

**This is the accepted manuscript version of the contribution published as:**

Li, Y., Wang, X., Zhu, Q., Xu, Y., **Fu, Q.**, Wang, T., Liao, C., Jiang, G. (2023):  
Organophosphate flame retardants in pregnant women: Sources, occurrence, and potential risks to pregnancy outcomes  
*Environ. Sci. Technol.* **57** (18), 7109 - 7128

**The publisher's version is available at:**

<https://doi.org/10.1021/acs.est.2c06503>

1 **Organophosphate flame retardants in pregnant women:**  
2 **Sources, occurrence, and potential risks to pregnancy**  
3 **outcomes**

4  
5 Yongting Li<sup>a,d</sup>, Xin Wang<sup>a,d</sup>, Qingqing Zhu<sup>a,d</sup>, Yaqian Xu<sup>a,b</sup>, Qiuguo Fu<sup>e</sup>,  
6 Thanh Wang<sup>f</sup>, Chunyang Liao<sup>a,b,c,d,\*</sup>, and Guibin Jiang<sup>a,b,c,d</sup>

7  
8 <sup>a</sup> State Key Laboratory of Environmental Chemistry and Ecotoxicology, Research  
9 Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing  
10 100085, China

11 <sup>b</sup> School of Environment, Hangzhou Institute for Advanced Study, UCAS, Hangzhou,  
12 Zhejiang 310024, China

13 <sup>c</sup> Hubei Key Laboratory of Environmental and Health Effects of Persistent Toxic  
14 Substances, Institute of Environment and Health, Jiangnan University, Wuhan, Hubei  
15 430056, China

16 <sup>d</sup> College of Resources and Environment, University of Chinese Academy of Sciences,  
17 Beijing 100049, China

18 <sup>e</sup> Department of Analytical Chemistry, Helmholtz Centre for Environmental Research  
19 (UFZ), Permoserstraße 15, 04318 Leipzig, Germany

20 <sup>f</sup> Man-Technology-Environment (MTM) Research Centre, Örebro University, Örebro  
21 701 82, Sweden

22

23

24 **\*Corresponding author:**

25 Research Center for Eco-Environmental Sciences

26 Chinese Academy of Sciences

27 Beijing 100085, China

28 Tel./Fax: 86-10-6291 6113

29 E-mail: cyliao@rcees.ac.cn

30

31           **Abstract**

32           Organophosphate flame retardants (OPFRs) are found in various environmental matrices  
33 and human samples. Exposure to OPFRs during gestation may interfere the pregnancy, for  
34 example, inducing maternal oxidative stress and maternal hypertension during pregnancy,  
35 interfering maternal and fetal thyroid hormone secretion and fetal neurodevelopment, and  
36 causing fetal metabolic abnormalities. However, the consequences of OPFR exposure on  
37 pregnant women, impact on mother-to-child transmission of OPFRs, and harmful effects on  
38 fetal and pregnancy outcomes have not been evaluated. This review describes the exposure to  
39 OPFRs in pregnant women worldwide, based on metabolites of OPFRs (mOPs) in urine for  
40 prenatal exposure and OPFRs in breast milk for postnatal exposure. Predictors of maternal  
41 exposure to OPFRs and variability of mOPs in urine have been discussed. Mother-to-child  
42 transmission pathways of OPFRs have been scrutinized, considering the levels of OPFRs and  
43 their metabolites in amniotic fluid, placenta, deciduae, chorionic villi, and cord blood. The  
44 results showed that bis(1,3-dichloro-2-propyl) phosphate (BDCIPP) and diphenyl phosphate  
45 (DPHP) were the two predominant mOPs in urine, with detection frequencies of > 90%. The  
46 estimated daily intake (EDI<sub>M</sub>) indicates low risk when infants are exposed to OPFRs from breast  
47 milk. Furthermore, higher exposure levels of OPFRs in pregnant women may increase the risk  
48 of adverse pregnancy outcomes and influence the developmental behavior of infants. This  
49 review summarizes the knowledge gaps of OPFRs in pregnant women and highlights the crucial  
50 steps for assessing health risks in susceptible populations, such as pregnant women and fetuses.

51   **Keywords:** Organophosphate flame retardants; Prenatal exposure; Mother-to-child transmission;  
52 Urine; Breast milk; Pregnancy outcome

53   **Synopsis:** This article reviews the global prenatal and postnatal exposure of pregnant women  
54 to OPFRs and reveals the extent and potential risks to pregnancy outcomes.

55

## 56 **1. Introduction**

57 Flame retardants (FRs) are added to various manufactured materials as functional additives  
58 to reduce the flammability of materials, prevent the occurrence and spread of fires, and protect  
59 human life and property. Polybrominated diphenyl ethers (PBDEs) were the most widely used  
60 FRs until the 2000s, but they have been gradually banned because of their persistence,  
61 bioaccumulation, and ecotoxicity in the environment.<sup>1</sup> Organophosphate flame retardants  
62 (OPFRs) are increasingly being used as alternatives. OPFRs have been widely used in various  
63 industries and chemicals, such as textiles, electronics, furniture foams, and plasticizers in rubber  
64 products.<sup>2-4</sup> The production and usage of OPFRs have dramatically increased in recent years.  
65 The global consumption of OPFRs increased to 680,000 metric tons in 2015, an annual increase  
66 of 7.9%.<sup>5</sup> The US, Europe, Japan, and Asia are the four largest markets for flame retardants in  
67 the world. Among them, the US and Europe have established stable markets as the earliest  
68 producers and users of flame retardants. For example, the production and usage of triphenyl  
69 phosphate (TPHP) was the highest in the US and Europe among aryl-OPFRs, and tris(1-chloro-  
70 2-propyl) phosphate (TCIPP) accounted for approximately 80% of Cl-OPFRs usage in the US  
71 and Europe.<sup>6,7</sup> In recent years, the flame retardant industries in Asia have increasingly expanded,  
72 with the Chinese flame retardant market playing a significant role.<sup>8</sup>

73 OPFRs are often added to materials physically without chemical bonding, which allows  
74 them to be continuously released into the environment through volatilization, abrasion, and  
75 leaching.<sup>9</sup> The widespread occurrence of OPFRs has been documented in a variety of  
76 environmental matrices, such as water, sediment, air, dust, and soil.<sup>1, 6, 10-13</sup> OPFRs can be  
77 detected in surface water and drinking water worldwide, with analogues concentrations as high  
78 as tens of ng/mL.<sup>14</sup> High levels of OPFRs in sediments can endanger aquatic ecosystems,  
79 leading to exposure to aquatic plants and ingestion by aquatic animals, which in turn can enter  
80 the human body through the food chain and potentially affect human health. OPFRs have been

81 widely detected in both indoor and outdoor air. The levels of OPFRs in indoor air can be as  
82 high as hundreds of ng/m<sup>3</sup>.<sup>15</sup> Because OPFRs can easily be released from building material,  
83 interior decorations, furniture, consumer products, and carpets into the indoor environment the  
84 concentration of OPFRs in indoor air is typically 1–3 orders of magnitude higher than that of  
85 outdoor air.<sup>16</sup> Similar to air samples, the concentration of OPFRs in indoor dust was  
86 significantly higher than that in outdoor dust. OPFRs were detected in indoor dust samples from  
87 more than 29 countries, including households, offices, dormitories, daycare centers, and in-  
88 vehicle areas, with concentrations ranging from a few to tens of µg/g. Langer et al. studied 10  
89 OPFRs in dust samples collected from children’s bedrooms (*n* = 500) and daycare centers (*n* =  
90 151), and found higher concentrations of OPFRs in daycare center dust samples than in  
91 household dust samples. Since children are more likely to be exposed to OPFRs than adults,  
92 this result deserves more attention.<sup>17</sup> In addition, OPFRs have been discovered in many human  
93 samples globally, including urine, hair, nails, placenta, breast milk, and amniotic fluid.<sup>18</sup> For  
94 example, concentrations of ∑OPFRs in breast milk samples from Asia were as high as 600 ng/g  
95 lipid wt, indicating that breastfeeding may result in considerable exposure of newborns to  
96 OPFRs.<sup>19</sup> Many toxicological experiments have shown that OPFRs and metabolites of OPFRs  
97 (mOPs) could cause different toxic effects on organisms (fish, birds, and humans), including  
98 endocrine disruption, neurotoxicity, hepatotoxicity, reproductive toxicity, and interference with  
99 embryonic development.<sup>20, 21</sup> Studies indicated that OPFRs have adverse effects on female  
100 reproduction by damaging the regulatory pathway mediated by the hypothalamic-pituitary-  
101 gonadal (HPG) axis.<sup>22, 23</sup> For example, the exposure of female zebrafish to  
102 tris(1,3-dichloro-2-propyl) phosphate (TDCIPP) inhibited the expression of genes involved in  
103 gonadal development, and resulted in decreased egg production and morphological alterations  
104 on the surface of eggs. The reduction in egg quality could eventually lead to poor reproductive  
105 outcomes.<sup>24</sup> OPFRs could be considered as typical endocrine disruptors that can interfere with

106 the regulation of endogenous hormones and lead to abnormal fertility on humans and animals,  
107 especially for thyroid hormones.<sup>25, 26</sup> Thyroid hormones have a positive effect on the  
108 development, growth, and cell differentiation; disturbance of thyroid hormone levels could  
109 result in adverse developmental outcomes such as obesity. Alterations in maternal thyroid  
110 function could also affect pregnancy outcomes, which pose potential risks for the growth and  
111 development of infants.<sup>25</sup>

112 However, studies of OPFRs exposure in pregnant women are limited. Exposure to  
113 environmental pollutants during fetal development and the whole life stage causes chronic  
114 adverse effects on health.<sup>27</sup> Prenatal exposure to environmental pollutants deserves more  
115 attention because gestation is a critical period for the formation and development of fetal organs.  
116 For pregnant women, prenatal exposure to pollutants not only affects embryonic development,  
117 thus interfering with the pregnancy, but also affects the internal environment, thereby  
118 endangering prenatal and postnatal health.<sup>28</sup> During pregnancy and lactation, maternal OPFRs  
119 could be transmitted to the fetus and baby mainly through transplacental and lactational  
120 behaviors. Owing to mother-to-child transmission, pregnant women's exposure to OPFRs from  
121 various environmental matrices can also cause adverse effects on the fetuses. Epidemiological  
122 and toxicological studies have shown that maternal exposure to OPFRs may result in adverse  
123 pregnancy outcomes and affect the development of the fetus. Therefore, a review of prenatal  
124 exposure to OPFRs and their potential risks to mothers and their offspring is of great  
125 significance.

126 There have been several review papers on OPFRs, including on the application and  
127 synthesis routes of OPFRs;<sup>29</sup> the occurrence, analysis techniques, and toxicity of OPFRs in  
128 biota;<sup>14, 16, 20, 30</sup> the concentration of OPFRs in food and human dietary exposure;<sup>31</sup> and the  
129 metabolism and metabolic pathways of OPFRs in organisms.<sup>5, 20, 32</sup> However, to the best of our  
130 knowledge, a review on the exposure of pregnant women to OPFRs, effects on mother-to-child

131 transmission of OPFRs, and adverse effects on fetus and pregnancy outcomes is lacking. To  
132 this end, based on measurements of urine and breast milk samples from pregnant women  
133 worldwide, the occurrence of OPFRs in pregnant women before and after delivery was  
134 discussed, and exposure pathways of OPFRs in pregnant women were compared in the current  
135 review. The predictors associated with OPFR levels in pregnant women were then examined.  
136 Several possible routes of mother-to-child transmission of OPFRs in pregnant women, before  
137 and after delivery, are summarized. Furthermore, based on the results of toxicological and  
138 epidemiological studies, the potential risks of OPFRs in pregnant women to the next generation  
139 were examined in terms of the fetuses, infants, and young children.

140

## 141 **2. Strategies for literature search and data collection**

142 This review compiled the literature on OPFRs published from January 2012 to December  
143 2022. The literatures were screened on the online database of Web of Science, PubMed, and  
144 ScienceDirect using the following keywords: “organophosphate flame retardants”,  
145 “organophosphate esters”, “organophosphates”, “prenatal exposure”, “maternal exposure”,  
146 “pregnant women”, and “pregnancy”. We screened these literatures based on the following  
147 criteria: (1) the studies examined OPFRs of pregnant women in a biological matrix (including  
148 urine, breast milk, placental, and amniotic fluid), (2) these studies described the possible effects  
149 of maternal levels of OPFRs on the offspring, (3) studies reported the mother-to-child  
150 transmission pathways of OPFRs. There is sufficient evidence on the prenatal exposure to  
151 OPFRs and the relevant pregnancy outcomes, but limited evidence for each specific pregnancy  
152 outcome, which makes the comprehensive evaluation of adverse effects difficult. Therefore, we  
153 performed a systematic scoping analysis for the associations between the prenatal exposure of  
154 pregnant women to OPFRs and the pregnancy outcomes. The screening strategies of literature  
155 were configured based on the PECO (Population, Exposure, Comparator and Outcome)

156 guidance.<sup>33</sup> The PECO statement was as following: Among pregnant women, what is the effect  
157 of the highest OPFR exposure compared to the lowest OPFR exposure on the pregnancy  
158 outcomes? P: among pregnant women, what is the effect of, E: the highest OPFR exposure  
159 during pregnancy, C: the lowest OPFR exposure during pregnancy, O: pregnancy outcomes.  
160 The study selection and data extraction were performed by two authors of this review (Yongting  
161 Li and Yaqian Xu). Literatures were further identified based on the following criteria: (1) studies  
162 monitoring the urinary mOPs in pregnant women, (2) studies examining the relationships  
163 between the prenatal exposure and potential risks of pregnancy outcomes (including neonatal  
164 birth weight, neonatal birth size, neonatal anthropometry, miscarriage, spontaneous abortion,  
165 gestational age, and neonatal thyroid hormones), (3) studies reporting different levels of the  
166 OPFR exposures or different degrees of adverse effects, (4) observational studies (including  
167 case control study, cohort study, and cross sectional survey), and (5) peer-reviewed literatures  
168 published in English. Exclusion criteria for the literatures were as follows: (1) conference  
169 abstracts, review articles, meta-analyses, (2) data originated from the same population or  
170 somewhat overlapping populations, and (3) animal research and/or the study populations  
171 without pregnant women. Overall, 11 literatures were collected based on the selection criteria,  
172 and the quality of final references were critically evaluated (**Figure 1**). Yongting Li and Yaqian  
173 Xu separately assessed the design and quality of the 11 included studies using the Newcastle-  
174 Ottawa Scale (NOS) for observational studies.<sup>34</sup> Any discrepancies on the scoring were resolved  
175 by discussion. Detailed information about the assessment of included studies can be found in  
176 **Table S1**.

177 Available data were collected for ten OPFRs and ten mOPs. The ten OPFRs were:  
178 chlorinated-OPFRs: tris(2-chloroethyl) phosphate (TCEP), TCIPP, tris(2-chloropropyl)  
179 phosphate (TCPP), and TDCIPP; aryl-OPFRs: TPHP, tricresyl phosphate (TCrP), and  
180 2-ethylhexyl-diphenyl phosphate (EHDPP); alkyl-OPFRs: tri-*n*-butyl phosphate (TNBP),

181 tris(2-butoxyethyl) phosphate (TBOEP), and tris(2-ethylhexyl) phosphate (TEHP). The ten  
182 mOPs were: di-n-butyl phosphate (DNBP, the metabolite of TNBP), bis(2-chloroethyl)  
183 phosphate (BCEP, the metabolite of TCEP), bis(1-chloro-2-propyl) phosphate (BCIPP, the  
184 metabolite of TCIPP), diphenyl phosphate (DPHP, the metabolite of TPHP), di-cresyl  
185 phosphate (DoCP & DpCP, the metabolite of TCrP), isopropylphenyl phenyl phosphate (ip-PPP,  
186 the metabolite of mono-substituted isopropyl triphenyl phosphate (mono-ITP)), bis(2-  
187 butoxyethyl) phosphate (BBOEP, the metabolite of TBOEP), tert-butyl-phenyl phenyl  
188 phosphate (tb-PPP, the metabolite of mono-substituted tert-butyl triphenyl phosphate (mono-  
189 TTP)), 1-hydroxyl-2-propyl bis(1-chloro-2-propyl) phosphate (BCIPHIPP, the metabolite of  
190 TCIPP), and bis(1,3-dichloro-2-propyl) phosphate (BDCIPP, the metabolite of TDCIPP). The  
191 molecular weights, CAS numbers, and log  $K_{ow}$  values of the OPFRs and mOPs are listed in  
192 **Table S2**.

193

### 194 **3. Results and Discussion**

#### 195 **3.1. Exposure pathways of OPFRs to pregnant women**

196 The exposure pathways for the pregnant women are generally the same as for the general  
197 population.<sup>35-38</sup> Individuals are typically exposed to and ingest OPFRs through dust ingestion,  
198 dietary intake, air inhalation, and skin contact. In this section, the exposure pathways of  
199 pregnant women to eight predominant OPFRs (TPHP, TNBP, TCEP, TCIPP, TCrP, TDCIPP,  
200 TBOEP, and TEHP) are summarized based on the literatures selected by the systematic review.  
201 The contribution of each exposure pathway to the total intake of OPFRs varied depending on  
202 the class of compounds and the compounds within the same class.

203 It has been noted that the characteristics of exposure to OPFRs are age-specific and that  
204 dietary intake is the main contributor to exposure to OPFRs, followed by dust ingestion.<sup>35</sup>  
205 Dietary intake is the primary pathway for TCEP, TCIPP, and TNBP, accounting for 84%, 77%,

206 and 93% of total ingestion, respectively.<sup>39</sup> OPFRs can be detected in agricultural products such  
207 as grains (rice, corn), vegetables (potatoes, cereals, tomatoes, cabbage, rape, carrots, broccoli,  
208 onions, and celery), fruits (apples, bananas, oranges, pears, peaches, citrus, strawberries, and  
209 grapes), meat, dairy products, and eggs around the world.<sup>29, 38-40</sup> Pregnant women and mothers  
210 have a higher daily consumption of OPFRs than other adults, perhaps due to their specialized  
211 prenatal and postnatal diets.<sup>35, 41</sup> Throughout the pregnancy and breastfeeding period, women  
212 should have a well-balanced diet and refuel frequently in order to obtain sufficient calories and  
213 nutrients.<sup>42,43</sup> They may consume more food rich in protein, vitamins, and healthy fats, which  
214 maybe contribute to a relative increase in their body burdens of OPFRs.<sup>44</sup> OPFRs can be  
215 frequently detected in cereals and meat.<sup>45-47</sup> For example, China has the highest levels of  
216  $\Sigma$ OPFRs in rice worldwide, as high as 802 ng/g dry weight (dw).<sup>48</sup> The median concentration  
217 of OPFRs in meats and fish collected from a local market in America was higher than those in  
218 dairy and cereal products.<sup>49</sup> The consumption of cereals and meats constitutes a significant  
219 portion of the dietary intake of OPFRs. Considering that Chinese and Americans consume rice  
220 and meat as staple foods respectively, the intake of OPFRs through rice and meat consumption  
221 may pose a potential risk to pregnant women.

222 Indoor air inhalation and dust ingestion are significant pathways of non-dietary exposure.  
223 Some studies have pointed out that the most prevalent exposure routes were indoor air and dust,  
224 followed by skin contact.<sup>50, 51</sup> Air inhalation is an important route of exposure to Cl-OPFRs,  
225 and it was estimated that the total intake of Cl-OPFRs through air inhalation exceeded that from  
226 dust ingestion.<sup>52</sup> The assessment of human exposure to OPFRs via air inhalation, dust ingestion,  
227 and dermal contact showed that air inhalation was the primary route of exposure to volatile  
228 OPFRs (TCIPP and TCEP), whereas dust ingestion was the most important route for less  
229 volatile OPFRs (TBOEP and TPHP).<sup>50, 51</sup> Dermal contact and dust ingestion account for almost  
230 60% of the total intake of TBOEP among the four exposure pathways.<sup>39</sup> Levels of OPFRs in

231 indoor air and dust are usually higher than those in outdoor, and indoor settings are therefore  
232 an important exposure environment.<sup>16, 20</sup> A French cohort study reported that pregnant women  
233 spent an average of more than 16.7 hours per day indoors throughout their pregnancy.<sup>53</sup> Similar  
234 results were found in several cohort studies from Spain, Canada, and Poland.<sup>54-56</sup> Previous  
235 research recommended that future exposure and epidemiological studies should reflect the  
236 increase of exposure from indoor environments.<sup>57</sup> Exposure to OPFRs through air inhalation  
237 and dust ingestion for pregnant women requires more attention. Considering that women  
238 primarily stay indoors during the third trimester and after giving birth, indoor air and dust may  
239 be an important exposure pathway for OPFRs. During pregnancy, it is advisable to improve  
240 indoor ventilation. Plastic medical devices can also be an important source of exposure to  
241 OPFRs during hospitalization. The concentration of OPFRs in the urine of hospitalized infants  
242 was higher than that in outpatient infants.<sup>58</sup> This result may be related to the use of medical  
243 equipment, which usually contains plasticizers and flame retardants that are composed of  
244 OPFRs.

245 Skin contact also leads to prenatal non-dietary exposure to OPFRs. A study from Nepal  
246 revealed that dermal absorption contributed more to human exposure than air inhalation and  
247 dust ingestion. The EDIs for  $\sum_8$ OPFRs for dermal absorption, air inhalation, and dust ingestion  
248 were 16.8 ng/kg bw/day, 0.98 ng/kg bw/day, and 0.98 ng/kg bw/day, respectively.<sup>59</sup> In addition,  
249 there are some specific pathways for the dermal absorption of OPFRs in women. Urinary mOP  
250 levels in women aged 18–44 years were associated with OPFR levels on mobile phones ( $p <$   
251  $0.05$ ).<sup>60</sup> In the e-waste dismantling areas, levels of OPFRs in hand wipes were similarly greater  
252 in females than those in males ( $p < 0.01$ ).<sup>61</sup> Furthermore, more frequent personal care product  
253 usage was associated with higher levels of mOPs in the urine of pregnant women.<sup>62</sup> Using  
254 silicone wristbands to assess the exposure to pollutants during pregnancy, it was found that the  
255 content of TPHP was positively correlated with nail polish usage ( $\beta = 0.27$ ; 95% confidence

256 interval (CI): 0.00, 0.55).<sup>63</sup> The content of DPHP was related to the usage of nail polish and  
257 perfumes in a study of urine samples from pregnant women ( $p < 0.05$ ).<sup>62</sup> The use of nail polish  
258 was associated with a 306% increase in urinary DPHP concentrations (95% CI: 129–610%;  
259  $p < 0.0001$ ) among women.<sup>64</sup> This may be due to TPHP replacing dibutyl phthalate as plasticizer  
260 to increase the flexibility and durability of nail polish.<sup>64</sup> The use of personal care products was  
261 also related to elevated levels of TCEP, TCIPP, TDCIPP, and their metabolites in the urine  
262 samples of pregnant women. The concentrations of BDCIPP, BCIPP, and ip-PPP are associated  
263 with the use of sunscreen, pesticides, and cosmetics ( $p = 0.01$ ), respectively.<sup>62, 64</sup> TPHP is an  
264 aryl-OPFR and has shown various endocrine and metabolic disrupting and abilities, as well as  
265 reproductive toxicity to females in animal and human experiments.<sup>65, 66</sup> TCEP, TCIPP, TDCIPP  
266 are typical Cl-OPFRs, which interfere with embryonic development, disturb neurodevelopment,  
267 and induce vascular toxicity.<sup>67-69</sup> Pregnant women should be careful with personal care products,  
268 especially nail polish, throughout their pregnancy. Given the relationship between dermal  
269 exposure of pregnant women to personal care products and mOPs in urine, the disparities in  
270 racial/ethnic usage patterns of personal care products can influence OPFRs exposure.<sup>70</sup> For  
271 example, Latina women use more cosmetics, black women use more hair products. Future  
272 prevention measures of OPFR exposure for pregnant women of different ethnicities need to be  
273 more differentiated.<sup>71</sup>

274         Pregnancy is an extremely vulnerable developmental stage. Endocrine system and  
275 metabolism of body water, protein, glucose, and lipid change a lot throughout the pregnancy.<sup>72</sup>  
276 Environmental and occupational hazards may impair early developmental processes and  
277 increase later-life vulnerability to disease.<sup>73</sup> Exposure to toxins might disturb the normal  
278 physiological environment of the mother and cause long-term adverse effects.<sup>74, 75</sup> In addition,  
279 the placental barrier is not sufficient to block all exogeneous chemicals, which would lead to

280 direct exposure of the fetus to toxins with adverse effects on fetal development.<sup>76-78</sup>

### 281 **3.2. Prenatal exposure to OPFRs**

282 Prenatal exposure to OPFRs can be detected in urine samples from pregnant women  
283 worldwide. Among these studies, urine is the main biomonitoring tool.<sup>79, 80</sup> Internal exposure  
284 estimation of OPFRs through the urinary monitoring can avoid the evaluation errors caused by  
285 external exposure assessment. Moreover, biomonitoring on mOPs reveals human exposure to  
286 OPFRs and relationships between internal and external exposure.<sup>32</sup> Prenatal exposure of  
287 pregnant women to OPFRs will be determined based on urine mOP concentrations (mostly  
288 diester metabolites). The mOPs of high concern in urinary monitoring include Cl-mOPs  
289 (BDCIPP, BCIPHIPP, BCIPP, and BCEP), aryl-mOPs (DPHP, and DoCP & DpCP), and alkyl-  
290 mOPs (DNBP, BBOEP, ip-PPP, and tb-PPP).

#### 291 **3.2.1. Levels of exposure to OPFRs in prenatal pregnant women**

292 Levels of mOPs in the urine of pregnant women worldwide are summarized in **Figure 2**.  
293 Analysis of urine samples (before delivery) of pregnant women from the United States, Canada,  
294 and China showed that BDCIPP and DPHP were the two predominant mOPs, with detection  
295 frequencies (DFs) of > 90% in almost all studies. In 2014, Hoffman et al. studied the levels of  
296 BDCIPP and DPHP in the urine samples of eight pregnant women from central North Carolina  
297 during different pregnancy stages.<sup>82</sup> BDCIPP and DPHP levels were detected in 38 of 39 urine  
298 samples with median concentrations of 1.1 and 1.6 ng/mL, respectively. This is the first study  
299 to monitor OPFRs levels in the urine of pregnant women, but the results were limited due to  
300 the small sample sizes. The samples were collected between 2011 and 2012. From 2003 to 2006,  
301 BDCIPP and DPHP levels in the same location were 1.85 and 1.31 ng/mL, respectively. The  
302 concentration of BDCIPP in urine samples collected in North Carolina from 2011 to 2012  
303 decreased by more than 40% from 2002 to 2005, whereas the concentration of DPHP increased  
304 by approximately 23%.

305 Although the sampling time difference between the two studies was several years and the  
306 DFs in all samples increased, the levels of BDCIPP and DPHP in the two studies were similar,  
307 which is surprising given that the production of OPFRs as alternatives to PBDEs has increased  
308 significantly since 2010.<sup>83</sup> Most of the samples collected after 2010 showed higher levels of  
309 BDCIPP than those collected from Cincinnati, Ohio from 2003 to 2006, but not all studies met  
310 this pattern. Most samples collected after 2010 had lower DPHP levels than those collected  
311 from Cincinnati, Ohio.<sup>84, 85</sup> As there were fewer urine monitoring studies conducted to before  
312 2010, this conclusion was insufficiently convincing. The levels of mOPs varied considerably  
313 across regions. For example, the concentration of BDCIPP in the urine of pregnant women in  
314 North Carolina is twice as high as that in Ohio. The concentration of DPHP in the urine of  
315 pregnant women on Rhode Island was lower than that in Ohio and North Carolina, where the  
316 concentrations were similar. BCEP, BCIPP, and ip-PPP had high DFs and concentrations in  
317 urine samples in the United States, in addition to BDCIPP and DPHP. For Chinese urine samples,  
318 the levels of mOPs in samples collected after 2010 were not significantly higher than those  
319 collected before 2010. Comparing the two batches of samples collected from Wuhan  
320 simultaneously, the DFs of several mOPs were significantly different, which may be related to  
321 the method of samples pretreatment. The composition and levels of urinary mOPs in pregnant  
322 women from three areas of China were considerably different. It is worth noting that the level  
323 of DPHP in pregnant women in Shanghai was approximately 1.75 times higher than that in the  
324 e-waste dismantling area of Guangdong Province. This result may be influenced by  
325 environmental exposure and living habits of urban women. In China and Canada, the levels of  
326 DPHP were an order of magnitude higher than those of BDCIPP. The levels of BDCIPP and  
327 DPHP were similar in the U.S. This indicates variances in OPFRs exposure among pregnant  
328 women in different countries and reflects the differences in OPFRs production and usage.  
329 Detailed information regarding mOPs in the urine of pregnant women is shown in **Table S3 (a)**.

### 3.2.2. Variation of urinary mOPs in pregnant women

Many researchers have monitored the concentrations of mOPs in urine samples at different stages of pregnancy to assess the temporal variation of mOPs and to test whether a single monitoring during pregnancy can reflect the whole pregnancy.

Using intraclass correlation coefficients (ICCs) to evaluate variability, ICCs values ranged from 0 to 1, indicating no reproducibility or perfect reproducibility. Samples were mainly collected in the first, second, and third trimesters, and after giving birth. Detailed information on the collection times and ICCs is provided in **Table 1**. The results showed that the reproducibility of samples collected from different regions for the same mOPs varies, such as the ICCs of BDCIPP in Northern Puerto Rico (ICCs: 0.23) and Maryland (ICCs: 0.59). Some studies have shown good reproducibility for different mOPs in urine collected from the same location, such as the ICCs of DPHP (ICCs: 0.4) and BDCIPP (ICCs: 0.4) in North Carolina. In general, the concentrations of mOPs are not consistent during the gestation period.<sup>86</sup> For example, data from North Carolina showed that the urine concentrations of BDCIPP and DPHP in this study were well consistent during the pregnancy period.<sup>82</sup> In Baltimore and Maryland, the variation degree of BDCIPP was consistent (ICCs: 0.42, 0.69), but several mOPs (DPHP, ip-PPP, tb-PPP, and BCIPP) exhibited substantial variability during pregnancy. DPHP and BDCIPP levels during pregnancy were consistent with the samples collected from Rhode Island and North Carolina, whereas BCEP showed comparable variability to BDCIPP and DPHP.<sup>82, 87</sup> The researchers examined the variability in urine mOPs of pregnant women from Ohio using a cohort of  $n = 357$ . The results demonstrated that the ICCs (0.24, 0.40) of mOPs showed high variability during pregnancy. Poor reproducibility of mOPs during pregnancy was also detected in Puerto Rico.<sup>62</sup> The weak reproducibility indicated that single monitoring during pregnancy in these populations cannot accurately reflect the levels throughout the whole pregnancy. The difference in excretion rate and renal function during pregnancy may account for these findings.

355 In the subsequent study in Puerto Rico ( $n = 48$ ), the urine concentrations of mOPs were  
356 measured during the three stages of pregnancy. However, the ICCs varied from 0.51 to 0.61,  
357 which was much higher than the stability obtained by detecting only the two stages. Similar  
358 stability was observed for BDCPP (ICC = 0.60), DPHP (ICC = 0.43), and BCEP (ICC = 0.50)  
359 in pregnant women on Rhode Island ( $n = 59$ ).<sup>87</sup> Urine mOP levels at different periods of  
360 pregnancy showed excellent consistency with the mixed samples. The variability of urine mOPs  
361 during pregnancy may be associated with physiological changes (e.g., blood volume, renal  
362 vascularity, oxygen demand, and energy metabolism) that affect the metabolism and excretion  
363 of OPFRs in pregnant women.<sup>72</sup>

### 364 **3.2.3. Predictors of mOPs in pregnant women before delivery**

365 Researchers investigated the relationships between sociodemographic predictors (such as  
366 age, ethnicity, pre-pregnancy body mass index (BMI), education, pregnancy parity, passive  
367 smoking frequency, sampling time, and sampling season) and exposure to OPFRs in pregnant  
368 women before delivery (**Figure 3**).

369 A study on the association between the prenatal BMI and mOP levels in urine found that  
370 relatively higher prenatal body weight positively correlates with mOP levels.<sup>87,88</sup> For example,  
371 it was found that the concentrations of BDCIPP, DPHP, and ip-PPP in pregnant women with  
372 overweight and obesity during pregnancy were higher than those in women with normal BMI.  
373 Women with the first pregnancy were found to have lower ip-PPP levels in urine samples ( $p =$   
374  $0.02$ ), but the level of DPHP was significantly higher ( $p = 0.02$ ).<sup>79</sup> Women with lower education  
375 had higher ip-PPP concentrations.<sup>79</sup> As for food, lower urine levels of BCEP were associated  
376 with more frequent consumption of meat (beef, pork, or lamb), lower urine concentrations of  
377 BDCIPP or DPHP were associated with frequent consumption of green leafy vegetables or  
378 carrots and citrus fruits, respectively. However, no significant effect of dietary factors on urine  
379 BCEP, BDCIPP, and DPHP was observed.<sup>87</sup> Among these studies, there are few studies on the

380 accumulation of mOPs in food, and no significant association between the dietary habits of  
381 pregnant women and mOPs has been found. Further studies on dietary exposures and food  
382 packaging analysis should be undertaken in the future to assess the presence of OPFRs. This is  
383 helpful for estimating the extent of OPFRs ingested through food. In addition, the sampling  
384 season may also affect mOPs levels in pregnant women's urine, and the concentrations of  
385 BDCIPP, DPHP, and BCIPHIPP in the samples collected in summer were significantly higher  
386 than those collected in winter, and the urine collection season was the most significant predictor  
387 of mOP levels.<sup>79, 85</sup> A study of sampling seasons showed similar results: urine concentrations of  
388 BDCIPP, DPHP, and ip-PPP are usually the lowest in winter.<sup>89</sup> These results indicate that the  
389 collection season could be an important confounder in future epidemiological studies using spot  
390 urine samples as a proxy for longer-term OPFRs exposure.<sup>79</sup>

391 These results further expand our understanding of how pregnant women are exposed to  
392 OPFRs and provide evidence for future studies on the potential risks of OPFRs. The  
393 relationships between different OPFRs and their structures, exposure pathways, and  
394 characteristics need to be further explored. Many epidemiological surveys have discussed only  
395 one class of pollutants, but humans are exposed to multiple environmental pollutants. For  
396 example, co-exposure of microplastics and TCEP increased oxidative stress and intestinal  
397 damage to earthworms comparing to control group, and co-exposure of graphene and TPHP  
398 increased TPHP accumulation in tissues of *Mytilus galloprovincialis*.<sup>90, 91</sup> Future  
399 epidemiological investigations need to focus on the synergistic effects of mixed exposures to  
400 these pollutants and the effects of multiple chemical exposure risks on the same adverse health  
401 outcomes and quantify these potential risks.

#### 402 **3.2.4. Health risks associated with prenatal exposure to OPFRs for women**

403 The frequent detection of mOPs in the urine of pregnant women is a cause for concern,  
404 since studies have shown a correlation between the concentration of DPHP in female urine and

405 serum-free and total thyroid hormone levels.<sup>92</sup> A study on the correlation between mOPs in the  
406 urine of premenopausal women and uterine fibroids showed that higher levels of BDCIPP and  
407 BBOEP in urine were positively correlated with the occurrence of uterine fibroids ( $p < 0.05$ ).<sup>93</sup>  
408 The estimated daily intakes of pregnant women derived from urine levels (EDI<sub>U</sub>) are presented  
409 in **Table S4**. Values of EDI<sub>U</sub> were approximately three orders of magnitude lower than the RfDs,  
410 suggesting a low risk of prenatal exposure to OPFRs. However, the molar ratio (F) of OPFRs  
411 is an important estimation parameter which has been limited studied.<sup>94, 95</sup> The varied F values  
412 of individual OPFRs indicated the necessity for accurate estimation of body burden.

413 Levels of OPFRs are associated with the occurrence of female-specific tumors, including  
414 papillary thyroid carcinoma, breast cancer, and cervical cancer ( $p < 0.05$  or  $p < 0.01$ ).<sup>88, 96</sup>  
415 Moreover, OPFRs can affect the synthesis of progesterone and human chorionic gonadotropin  
416 in human placental choriocarcinoma cells.<sup>97</sup> OPFRs exposure generates oxidative stress and  
417 DNA damage, suggesting that OPFR exposure during pregnancy causes DNA damage or  
418 oxidative stress in pregnant women, disrupts thyroid secretion, and undermines thyroid  
419 homeostasis.<sup>98, 99</sup> Prenatal stress can trigger changes in placental serotonin synthesis during the  
420 critical period of embryonic development, affect the development of the fetal brain, and increase  
421 the risk of mental illness in later years.<sup>100</sup>

### 422 **3.3. Mother-to-child transmission**

423 It has been found that exogenous compounds, such as perfluoroalkyl substances and  
424 phthalate metabolites, can cross the placental barrier, enter the embryonic circulatory system,  
425 and harm the fetus.<sup>101, 102</sup> Assessing the mother-to-child transmission capacity of exogenous  
426 compounds in the womb is essential for understanding the risks to healthy fetal growth. This  
427 section summarizes the maternal-infant transmission efficiencies of several OPFRs in amniotic  
428 fluid, placenta, cord blood, and other samples and the relevant influencing factors.

#### 429 **3.3.1. Before the placenta matures**

430 During the first eight weeks of gestation, the placenta is immature. Embryos are therefore  
431 easily exposed to contaminants. The villi are evenly distributed on the surface of the entire  
432 chorionic membrane. As the embryo grows, the villi adjacent to the decidua develop a rich  
433 nutrients and blood supply, and the stem branches become luxuriant, called the dense chorion,  
434 which constitutes the fetal part of the placenta. As a direct maternal-embryo interface, decidua  
435 and chorionic villi are significant components for the exchange and metabolism of nutrients,  
436 gas, wastes, and pollutants during pregnancy.<sup>103, 104</sup> Therefore, the maternal transfer of OPFRs  
437 was also affected by the different metabolic processes of OPFRs in the deciduae and chorionic  
438 villi. In a study of OPFRs levels in human decidua and chorionic villi, EHDPP and DPHP were  
439 frequently (DF: 96%) detected in chorionic villi, with median concentrations of 13.6 ng/g dw  
440 and 11.1 ng/g dw, respectively, much higher than those of decidua samples. The DFs of most  
441 OPFRs were higher in the chorionic villi than in the decidua.<sup>105</sup> To our knowledge, this is the  
442 first study to report the levels of OPFRs in human chorionic villi. Before placental formation,  
443 the embryo has been exposed to pollutants and has undergone exogenous compound transfer  
444 with the mother, according to the results. In addition, the maternal transfer efficiency (CMR)  
445 of the target compound was quantitatively assessed by calculating the ratio of the OPFR  
446 concentrations in the chorionic villi (containing embryos) to those in the maternal deciduae. It  
447 was found that the maternal CMRs were independent of the lipid content of the samples but had  
448 a significant positive correlation with the log  $K_{ow}$  values of OPFRs ( $p = 0.003$ ).<sup>105</sup> The log  $K_{ow}$   
449 values are usually related to the binding ability to proteins. The stronger the binding ability to  
450 transthyretin (TTR), the higher the CMRs of EHDPP, TPHP, TNBP, and TCEP, which further  
451 indicates that the binding ability contributes to the maternal transfer of OPFRs.<sup>105</sup>

### 452 **3.3.2. After the placenta matures**

453 The placenta is a vital organ that maintains fetal growth and embryonic development. It  
454 connects the fetal and mother's circulatory systems and selectively transports molecules

455 between them, protecting the fetus from exogenous compounds.<sup>106</sup> Nutrients and oxygen are  
456 transported between mother and fetus through the placenta. Even if the placenta has a barrier  
457 effect, some exogenous compounds may pass through the placental barrier, causing adverse  
458 effects on the fetus.<sup>107</sup> Changes in the maternal can significantly impact placenta implantation,  
459 growth, nutrient transfer, and hormones.<sup>101</sup> The analysis of contaminant levels in the placenta  
460 is important because contaminant in the placenta are not only biomarkers of internal maternal  
461 exposure to these chemicals but are also appropriate biomarkers for prenatal exposure of the  
462 fetus throughout pregnancy. A study found that the concentration of TCEP was the highest in  
463 the human placenta, accounting for 58% of all OPFRs.<sup>108</sup> Offspring sex-specific accumulation  
464 was also found in the placentas of Wistar rats exposed to FM550 during gestation.<sup>109</sup>

465 As a group of compounds with various physicochemical properties, OPFRs have been  
466 shown to have the potential for transplacental transfer in organisms. Experiments with paired  
467 samples of cord blood and maternal blood showed that the transplacental transfer of OPFRs and  
468 mOPs correlated with their log  $K_{ow}$  values. The concentration ratio (C:M) of OPFRs in cord  
469 blood versus those in maternal blood showed a parabolic relationship with the increasing log  
470  $K_{ow}$  values. Moreover, the transplacental transfer efficiencies of the alkyl-OPFRs were lower  
471 than those of the aryl-OPFRs. In addition, the transplacental behavior of OPFRs and mOPs is  
472 related to the binding affinity of transporters in the placenta and metabolic enzymes in the fetus.  
473 For example, the C:M ratio of TCrP is the highest due to the strong binding affinity between  
474 TCrP and TTR for the molecular docking results, suggesting that the transplacental transfer of  
475 TCrP is active transport. OPFRs with log  $K_{ow}$  of 1.63–4.70 were mainly involved in  
476 transplacental transfer by passive diffusion.<sup>110</sup> Di-mOPs were also detected in blood samples at  
477 significantly lower concentrations than OPFRs. Moreover, the concentrations of different di-  
478 mOPs in cord blood and maternal blood were different, which may be related to their excretion  
479 rates and the metabolism of their parent compounds in the fetus.<sup>110</sup> For Wistar rats exposed to

480 FM550 during pregnancy and postpartum, the transfer of the brominated component by  
481 lactation was 200–300 times that of the transplacental transfer, but the organophosphate  
482 components were not detected in the fetus. The results indicated that TPHP and ITP had not  
483 been transferred by pregnancy or lactation.<sup>111</sup> This may be because liver microsomes quickly  
484 metabolize TPHP.<sup>95</sup> The results of whole-body autoradiographic disposition indicated that TCrP  
485 can be transported to the fetus via transplacental behavior in ICR mice.<sup>112</sup> More studies are  
486 needed on the metabolic profile of different OPFRs to understand their transplacental transfer  
487 capacity.

488 In addition to transplacental transfer, the fetus is exposed to environmental contaminants  
489 through amniotic fluid. Amniotic fluid is the only living environment for the fetus before birth,  
490 surrounding and protecting the fetus. Among environmental chemicals, the heavy metals  
491 mercury, perfluorooctane sulfonates, and organochlorine have been detected in amniotic  
492 fluid.<sup>113-115</sup> mOPs were also detected in amniotic fluid samples collected from the e-waste  
493 dismantling area, with the highest concentration of DNBP (1.3 ng/mL), followed by DPHP  
494 (0.12 ng/mL), and the level of DNBP was an order of magnitude higher than that of DPHP. This  
495 result suggests that we need to pay more attention to the use and release of TNBP in electronic  
496 products.<sup>116</sup> The distribution and composition of mOPs in urine and amniotic fluid samples  
497 from the same mother were similar or consistent. The concentration in amniotic fluid is  
498 generally lower than that in urine, which may be due to the role of the placental barrier and the  
499 difference in fetal and maternal metabolic capacities.

### 500 **3.4. Exposure to OPFRs after delivery**

#### 501 **3.4.1. Levels of OPFRs in breast milk of among postnatal mothers**

502 The major nutritional source for infants is breast milk, which contains proteins,  
503 carbohydrates, vitamins, antibodies, and fats. It also includes many exogenous pollutants  
504 resulting from the mother's exposure to food, medicine, and the environment.<sup>117</sup> These

505 pollutants are the primary causes of newborns' exposure to environmental pollution. Due to the  
506 immature immunological and metabolic system of newborns, infants are frequently overloaded  
507 with external pollutants compared to their bodies.<sup>118</sup> The study on the level of OPFRs in breast  
508 milk helps to understand the OPFRs exposure of infants. Moreover, breast milk has been  
509 suggested by the World Health Organization as a perfect matrix for monitoring human  
510 environmental pollutants owing to non-invasive sampling and easy accessing.<sup>119, 120</sup>  
511 Concentrations of OPFRs in breast milk samples of postnatal mothers worldwide are  
512 summarized in **Figure 2**. OPFRs of high concern in breast milk include Cl-OPFRs (TCEP,  
513 TCIPP, and TDCIPP), aryl-OPFRs (TPHP, TCrP, and EHDPP), and alkyl-OPFRs (TNBP,  
514 TBOEP, and TEHP). Among them, the DFs of TPHP, TNBP, TCIPP, and TEHP were relatively  
515 higher (61–99%). The composition and proportion of OPFRs varied greatly in breast milk  
516 samples from different countries. Research on OPFRs in breast milk began in 2009, and these  
517 samples were collected from regions of the Swedish National Food Administration.<sup>9</sup> The  
518 concentration of TCIPP (45 ng/g lipid) was the highest in all samples, followed by TNBP (12  
519 ng/g lipid) and TPHP (8.5 ng/g lipid). Moreover, comparing breast milk samples collected in  
520 1997, 1998, and 2006 in Uppsala (a city in southeast Sweden), it was found that the  
521 concentration of TBOEP ten years ago was much higher than that at present. The DFs of TCIPP,  
522 TEHP, and TCEP increased significantly (e.g., the DF of TCIPP increased by 20 to 82% ten  
523 years later), whereas the DFs of the remaining OPFRs (TPHP, EHDPP, TNBP, and TBOEP) did  
524 not increase significantly. The level of TCIPP in Seattle is an order of magnitude higher than  
525 that of the national Children's Study sample repository, and TCIPP has the highest proportion  
526 of OPFRs in breast milk samples from the U.S. and Australia.<sup>121</sup> TCIPP accounts for 50% of  
527 total OPFRs, which may be attributed to its slow biotransformation in vivo.<sup>122</sup> Nearly 10 years  
528 have passed since the samples were collected, which may be related to the increased production  
529 and use of TCIPP in the U.S. market in recent years. Nevertheless, the level of TBOEP

530 decreased by approximately 1 ng/mL.<sup>119, 123</sup> The average and highest EDIs of OPFRs for adults  
531 were approximately two orders of magnitude lower than the corresponding reported references  
532 doses (RfDs), suggesting a low non-carcinogenic risk of OPFRs in pregnant women.<sup>35, 124</sup> The  
533 composition and proportion of OPFRs in breast milk in Asian countries and regions differs from  
534 those in Western countries. TCEP, TPHP, and TEHP had the highest percentages of all the  
535 OPFRs. The concentration of OPFRs in the Philippines is 1.5–2 times higher than in Japan,  
536 Vietnam, and Sweden. This difference may be because the breast milk samples from Filipino  
537 were collected from waste facilities. In this study, the DFs of TCEP, TNBP, and TCrP in breast  
538 milk samples were similar to those in indoor dust in the Philippines.<sup>125</sup> This finding indicated  
539 that the exposure pathways for OPFRs were from sources other than indoor dust, resulting in  
540 detectable concentrations of OPFRs in breast milk that are comparable to those of indoor dust.  
541 However, the proportion of TCEP in breast milk was higher than that in indoor dust, indicating  
542 that TCEP has a higher transfer rate to breast milk or biological accumulation potential than  
543 other OPFRs after entering the human body. In human liver microsome incubations, TCEP  
544 displayed good persistence with extremely low clearance rates (0.0006 mL/mg protein/min).<sup>94</sup>  
545 There have been few studies on mOPs in breast milk samples. Only one study has stated that  
546 the DFs of DNBP and DPHP were high. DNBP and DPHP accounted for a large proportion of  
547 the total mOPs.<sup>123</sup> The concentrations of DNBP and DPHP were positively correlated with their  
548 parent compounds TNBP and TPHP. Although these findings may be associated with the rapid  
549 metabolism of TNBP and TPHP in vivo, TNBP and TPHP may be transferred through the  
550 maternal blood.

551 Children could be more easily exposed to OPFRs than adults.<sup>126</sup> EDIs is higher in younger  
552 individuals, for infants it is mainly due to the intake of breast milk.<sup>35</sup> Children are also exposed  
553 to OPFRs by contact with toys, including dermal contact, hand-to-mouth contact, and mouthing.  
554 Although dermal contact is the primary pathway of exposure, the risk of exposure to OPFRs

555 through toys is low.<sup>127</sup> Infants may consume formula or solid foods in addition to breast milk.  
556 Although most OPFRs are detected frequently in these foods, the daily consumption of OPFRs  
557 by infants did not pose a health risk, with EDIs of OPFRs about 2-3 orders of magnitude lower  
558 than those of RfDs.<sup>128</sup> Based on the concentration of OPFRs in breast milk, the EDI<sub>M</sub> for infants  
559 was estimated to be significantly lower than the corresponding RfDs for OPFRs. Many studies  
560 have confirmed that the amount of OPFRs consumed by infants through breast milk were much  
561 higher than that through skin contact or dust inhalation. For example, in Australia, the EDI<sub>M</sub> of  
562 TCEP, TNBP, and TEHP by lactation was higher than that by air and dust ingestion, indicating  
563 higher exposure through breastfeeding.<sup>121</sup> Notably, the sample size of this study was small, the  
564 results were not representative, and there were significant differences in concentrations among  
565 the three samples. The EDI<sub>M</sub> of TBOEP (1380 ng/kg bw/day) and TDCIPP (980 ng/kg bw/day)  
566 in Japan and the EDI<sub>M</sub> of TCEP (1610 ng/kg bw/day) in the Philippines were close to the RfDs,  
567 and other EDI<sub>M</sub> of OPFRs were lower than their RfDs. The level of OPFRs in Beijing was high  
568 and was higher than that in North America, Europe, and other Asian countries, indicating that  
569 Beijing infants were highly exposed to OPFRs.<sup>129</sup> OPFRs in breast milk have no significant  
570 impact on infants' health. However, additional intake of OPFRs, such as food and dust, by  
571 infants may synergistically cause health risks. Detailed information on the OPFRs in breast  
572 milk is provided in **Table S3 (b)**. Detailed information about the EDI<sub>M</sub> of OPFRs through  
573 breastfeeding is shown in **Table 2**.

#### 574 **3.4.2. Predictors of OPFRs exposure among postnatal mothers**

575 Exposure to lipophilic pollutants in human breast milk is often associated with maternal  
576 age and dietary preferences.<sup>130</sup>

577 For age, it was observed that the concentrations of TNBP, TEHP, DNBP,  $\Sigma$ di-OPE, and  
578  $\Sigma$ tri-OPE were negatively correlated with maternal age ( $p < 0.05$ ).<sup>123</sup> However, there was no  
579 significant relationship between the concentrations of OPFRs in breast milk and age. This may

580 be due to the limited sample size, short half-life of OPFRs in humans, and the fact that the  
581 concentration of OPFRs in breast milk only represents short-term exposure. Most OPFRs were  
582 not significantly associated with racial characteristics. Only TBOEP was found to be twice  
583 lower in Spanish mothers (0.765 ng/mL) than in non-Spanish mothers (1.48 ng/mL) ( $p =$   
584 0.041).<sup>119</sup> Breastfeeding and excretion can reduce the content of OPFRs in the maternal body.  
585 Several studies have provided evidence to support this conclusion. The concentrations of TCEP,  
586 TEHP, and alkyl-OPFRs in the breast milk of multipara are lower.<sup>19, 129</sup> However, in Japan, this  
587 conclusion is contrary, which may be related to Japanese women's occupation, diet patterns,  
588 and habits of using products containing OPFRs.<sup>119</sup> Only high concentrations of EHDPP were  
589 found in breast milk samples provided by highly educated mothers.<sup>129</sup> The features of pre-  
590 pregnancy body weight or pre-pregnancy BMI were rarely found to be associated with the  
591 exposure of OPFRs in breast milk. Several studies found no statistical significance between  
592 BMI and OPFRs levels, and the difference was not obvious.<sup>19, 119, 123</sup> Only TCEP showed a  
593 significant difference in all groups, and pre-pregnancy BMI was positively correlated with the  
594 concentration of TCEP in breast milk.<sup>129</sup> Eating habits had little effect on OPFRs concentrations  
595 in breast milk. Mothers who ate more eggs had higher levels of TPhP in their breast milk.<sup>129</sup>  
596 Dietary habits had little effect on OPFRs accumulation in the placenta. For example, different  
597 amounts of visceral consumption during pregnancy resulted in different placental of TPhP ( $p <$   
598 0.05) and TCrP ( $p < 0.05$ ). Higher consumption of vegetables before pregnancy resulted in  
599 higher placental TCIPP concentrations ( $p < 0.05$ ). Higher concentrations of  $\sum_9$ OPFRs were  
600 associated with higher alcohol consumption in women before pregnancy ( $p < 0.05$ ).<sup>108</sup> The  
601 concentrations of  $\sum$ OPFRs were higher in the breast milk of mothers living in the suburbs. The  
602 concentration of TNBP is higher in the breast milk of mothers living in urban cities.<sup>129</sup> For  
603 behavioral habits, higher concentrations of OPFRs were observed in women with lower  
604 handwashing frequencies, although the difference was insignificant.<sup>123</sup> This helps us understand

605 how mothers behave or eat after delivery could reduce the levels of OPFRs in breast milk and  
606 reduce the potential impact of breastfeeding on infants since breast milk is a major food source.

### 607 **3.5. Potential risks of infants about maternal exposure to OPFRs**

#### 608 **3.5.1. Toxicity of OPFRs to the fetus in the womb**

609 Many animal experiments have shown that OPFRs have endocrine disruption effects, acute  
610 toxicity, developmental toxicity, reproductive toxicity, neurotoxicity, carcinogenicity, and  
611 teratogenicity, causing adverse developmental consequences in larvae. Acute exposure of  
612 embryos to OPFRs adversely affects embryo development, including inhibition of proliferation  
613 and cardiac differentiation of embryonic stem cells,<sup>131, 132</sup> inhibition of gene expression of HPT  
614 and GH/IGF axis,<sup>133, 134</sup> inhibition of gene expression related to neural development,<sup>68, 135</sup>  
615 cardiac toxicity during embryonic development,<sup>136-138</sup> and developmental neurotoxicity.<sup>67, 139</sup>

616 In zebrafish, exposure to TDCIPP at 0.75h after fertilization leads to dose-dependent delay  
617 or retardation of the ectoblast during the blastula and gastrula stages.<sup>67</sup> The typical  
618 developmental trajectory of zebrafish embryos is changed by inducing the formation of defects  
619 and abnormal germ layers of the gastrula, eventually leading to embryo malformation,  
620 developmental anomalies, and increased death rates. The developmental anomaly of zebrafish  
621 embryos caused by TDCIPP contains adverse effects on embryonic tail fin development,  
622 including spinal curvature, defects, and tip damage of tail fin.<sup>140, 141</sup> The dose-dependent  
623 inhibition of TDCIPP on vascular development was also observed in zebrafish embryos.<sup>69</sup> The  
624 growth and metabolic inhibition that adversely affected health in Japanese quail chicks were  
625 related to TPHP exposure during embryonic periods.<sup>142</sup> TCEP was observed to specifically  
626 affect cardiovascular development in the shell-less incubation system of chicken embryos.<sup>143</sup>  
627 Exposure to OPFRs during the embryonic stage also affects brain development by damaging  
628 the normal function of the rat placenta.<sup>144</sup> Early mouse embryo development was dose-  
629 dependently inhibited by TDCIPP (Oral LD50 = 2250 mg/kg), with 10  $\mu$ M TDCPP reducing

630 blastocyst formation and 100  $\mu$ M TDCIPP being deadly to mice embryos.<sup>145</sup> Acute exposure to  
631 TPHP (Oral LD50 = 1320 mg/kg) inhibited mouse embryonic stem cell growth in a dose-  
632 dependent manner.<sup>132</sup> It is noteworthy that specific concentrations of OPFRs causing  
633 developmental toxicity, neurotoxicity, cardiotoxicity, and hepatotoxicity in zebrafish are within  
634 the upper limit of the levels of OPFRs in indoor dust, human breast milk, plasma, and urine.<sup>146</sup>  
635 To clarify the damage to humans, it is required to examine the embryonic development toxicity  
636 produced by maternal exposure to OPFRs and to fully comprehend the mechanism and  
637 toxicokinetic features.

### 638 **3.5.2. Effects on pregnancy outcomes**

639 Epidemiological studies examined the relationships between the concentrations of OPFRs  
640 in mothers and the gestational age, birth weight, alternations in neonatal thyroid hormones, and  
641 adverse pregnancy outcomes, such as spontaneous abortion and premature delivery. A  
642 systematic evaluation of 11 publications examined the effect of the prenatal OPFR exposure on  
643 pregnancy outcomes. These included nine cohort studies and two case-control studies,  
644 involving 2434 participants in total. Four studies examined the association between the  
645 exposure to OPFRs during pregnancy and the neonatal birth weight.<sup>80, 89, 147, 148</sup> Three articles  
646 discussed the effects of the prenatal OPFR exposure on neonatal hormones, including thyroid  
647 hormone, thyroid stimulating hormone, insulin, and leptin.<sup>89, 149, 150</sup> Four studies investigated  
648 the association between the prenatal exposure to OPFRs and the gestational age.<sup>80, 89, 151, 152</sup> Two  
649 studies suggested a potential relationship between the exposure to OPFRs during pregnancy  
650 and the risk of miscarriage.<sup>153, 154</sup>

651 Prenatal exposure to OPFRs may disturb fetal growth and influence birth weight. A few  
652 studies reported that the levels of urinary mOPs in pregnant women are associated with the birth  
653 weight of the newborn.<sup>80, 147</sup> For example, higher concentrations of BDCIPP were associated  
654 with a higher BMI in newborns (n = 76).<sup>89</sup> The relationships between urinary mOPs collected

655 at different stages of pregnancy and birth weight of the newborns were different.<sup>80, 85, 88</sup> For  
656 example, the concentrations of ip-PPP, BDCIPP, and BBOEP in the third trimester; 4-HO-  
657 DPHP in the second trimester; and DPHP in the first trimester were negatively correlated with  
658 birth weight ( $p < 0.05$ ).<sup>80, 148</sup> However, these studies did not find a significant correlation  
659 between the prenatal OPFR levels and the neonatal birth weight.<sup>80, 89, 151</sup> Moreover, the effects  
660 of mOPs in maternal urine on fetal birth weight were sex-specific. Crawford et al. showed that  
661 the levels of BDCIPP during pregnancy ( $n = 56$ ) were associated with the higher weight gain  
662 of the male fetus after the first six weeks of life ( $\beta$  (the mean change in infant anthropometrics  
663 at six weeks postpartum) = 0.14 kg, 95% CI: 0.03–0.24,  $p$ -for-EM (effect modification) = 0.02),  
664 but a negative correlation between DPHP and weight gain was found in female fetuses ( $\beta =$   
665  $-0.19$  kg, 95% CI:  $-0.36$  to  $-0.02$ ,  $p$ -for-EM = 0.02).<sup>151</sup> In a Nested Case-Control study in  
666 China ( $n = 339$ ), a significant positive correlation between DPHP in pregnant women's urine  
667 and the risk of low birth weight was only observed in female newborns ( $p < 0.01$ ).<sup>147</sup> Similar  
668 results were observed in animals. Embryonic chicken exposure to TDCIPP leads to a weight  
669 loss of 7% during hatching.<sup>155</sup> Prenatal exposure to TDCIPP leads to the production of lighter-  
670 weight rat cubs.<sup>156</sup> Low birth weight is one of the leading causes of newborn mortality and  
671 sickness, and it also affects the health of adults.

672 The concentration of mOPs in maternal urine is positively correlated with thyroid hormone  
673 levels in newborn blood.<sup>150</sup> DNBP and DPHP exhibited a positive connection with the neonatal  
674 TSH above the 5th quantile ( $p < 0.05$ ) and the 5th–85th quantiles, respectively.<sup>150</sup> A sex-specific  
675 association between the prenatal exposure to OPFRs and the neonatal TSH levels was observed  
676 in one cohort study ( $n = 102$ ), but not observed in another cohort study ( $n = 298$ ).<sup>86, 149</sup> Several  
677 animal toxicological studies have demonstrated that embryo exposure to OPFRs disrupted the  
678 development of thyroid and altered the release of thyroid hormones.<sup>134, 142, 156-158</sup> TSH plays an  
679 essential role in maintenance of normal thyroid function and fetal growth. More studies are

680 needed to reveal the relationship between prenatal exposure to OPFRs and neonatal TSH levels.

681 Some studies have also found that urine mOPs in pregnant women are associated with  
682 pregnancy duration. An interquartile range-increase in DPHP levels was associated with a  
683 decreased risk of gestational age (odds ratio (OR) = 0.40; 95% CI: 0.18–0.87).<sup>152</sup> Urine  
684 BDCIPP (95% CI: 1.08–14.78) and ip-PPP (95% CI: 1.23–17.06) were associated with  
685 shortened pregnancy and increased risk of premature delivery in female infants, whereas ip-  
686 PPP concentrations (OR = 0.21; 95% CI: 0.06–0.68) were associated with a decreased risk of  
687 premature delivery in male infants.<sup>80</sup> However, Crawford et al. (n = 56) and Kuiper et al. (n =  
688 76) found no significant associations between the urine mOP concentrations in pregnant women  
689 and the gestational age.<sup>89, 151</sup> Toxicological results also confirmed the association between  
690 OPFRs exposure and pregnancy time. Exposure to TCEP (> 20 µg/L) in zebrafish embryos  
691 could lead to incubation delay due to the disruption of TCEP to thyroid hormone homeostasis.<sup>159</sup>

692 In a study of urine mOPs of pregnant women with spontaneous abortion (SAB) and healthy  
693 controls, the increased risks of fetal chromosome abnormalities and SAB were associated with  
694 higher BDCIPP (OR = 2.34; 95% CI: 1.14–4.81) and BCIPP ( $p < 0.001$ ) levels, respectively.<sup>153</sup>  
695 Pregnant women exposed to OPFRs before delivery with assisted reproductive technology  
696 (ART) may be related to poor pregnancy outcomes ( $p < 0.05$ ).<sup>160</sup> Levels of urine DPHP and ip-  
697 PPP are inversely proportional to the proportion of successful fertilization, implantation,  
698 clinical pregnancy, and live-born.<sup>154</sup> Early termination of pregnancy may be related to the level  
699 of urine DPHP among women conceiving with ART.<sup>161</sup> SAB is the most common adverse  
700 pregnancy outcome, defined as fetal demise prior to 20 completed weeks of gestation in North  
701 America.<sup>162</sup> Few studies have examined the relationship between prenatal exposure to OPFRs  
702 and abortion. Some studies have shown that the concentration of OPFRs in pregnant women is  
703 related to oxidative stress. Higher levels of oxidative stress lead to adverse pregnancy outcomes  
704 such as premature delivery and preeclampsia. This may be due to the influence of OPFRs and

705 their mOPs on antioxidant enzyme activity or related gene expression.<sup>163</sup> OPFRs are  
706 increasingly being utilized and produced as alternatives to traditional flame retardants, and  
707 prenatal exposure to OPFRs will likewise increase. Future studies should focus on the  
708 mechanism underlying the relationship between prenatal exposure to OPFRs and a higher SAB  
709 risk.

### 710 **3.5.3. Effects on developmental behaviors of infants**

711 Childhood is a critical period of social behavior development, and bad behavior and habits  
712 often persist throughout childhood.<sup>164</sup> Exposure to environmental pollutants may adversely  
713 affect their behavioral and emotional development.<sup>165</sup>

714 Exposure to OPFRs throughout pregnancy and infancy may affect cognitive and  
715 behavioral development in infants.<sup>166</sup> Animal experiments showed that exposure of zebrafish  
716 embryos to TPHP could interfere with the development of larvae's eyes and muscle tissues.<sup>167</sup>  
717 Exposure to TPHP during pregnancy in rats will accelerate the onset of diabetes mellitus type  
718 2 in 3.5 months old rats and lead to adipose accumulation.<sup>168</sup> By affecting lipid metabolism and  
719 intestinal function in adult mice, obesity occurs in adult mice with metabolic dysfunction.<sup>169</sup>  
720 *Coturnix japonica* (Japanese quail chickens) exposed to TPHP with a low dose (5 ng/g) would  
721 be more aggressive, and with a high dose (100 ng/g) would increase their boldness.<sup>170</sup> Exposure  
722 of juvenile yellow catfish to TCEP can reduce the survival rate (100 µg/L) and specific growth  
723 rate (10 and 100 µg/L).<sup>171</sup> Exposure of mice to OPFRs during pregnancy can also change the  
724 movement, and anxiety-like behavior of offspring, and these changes have sex-specific  
725 effects.<sup>172</sup> The continuous exposure of male rats to TDCIPP (25–250 mg/kg) within 28 days  
726 after birth will inhibit their sexual behavior and reduce testicular growth in a dose-dependent  
727 manner.<sup>173</sup> Early-life zebrafish exposure to TDCIPP can inhibit the growth and gene expression  
728 of motor neurons, affect the cholinergic system, and lead to anxiety in adult females, resulting  
729 in delayed neurotoxicity in adult zebrafish.<sup>135, 174</sup>

730 Epidemiological findings suggest that prenatal and early life exposure to OPFRs can affect  
731 infant cognitive and behavioral development. For example, poor social skills, asthma, and  
732 allergic symptoms in children are related to the concentration of OPFRs in indoor dust.<sup>164, 175,</sup>  
733 <sup>176</sup> The decrease in children's memory and full-scale intelligence quotient was related to  
734 maternal prenatal exposure to TPHP.<sup>177</sup> Moreover, the effects of OPFRs on developmental  
735 behaviors were sex-specific. The statistical results show that prenatal exposure to chlorinated-  
736 OPFRs, especially TDCIPP, may be inversely proportional to neurodevelopment in boys but  
737 not in girls.<sup>178</sup> In summary, epidemiological studies on the effects of OPFRs prenatal exposure  
738 to OPFRs on children's cognition and behavioral are minimal. Therefore, more robust  
739 inferences about the potential developmental risks of OPFRs exposure in children are necessary.

740

#### 741 **4. Conclusions and perspectives**

742 The exposure of pregnant women to OPFRs varies before and after delivery. The levels  
743 and proportions of mOPs in urine and OPFRs in breast milk were distinct. However, it is  
744 undeniable that pregnant women are widely exposed to TDCIPP and TPHP before delivery.  
745 Although the production of OPFRs has increased rapidly in the past 20 years, analysis of  
746 maternal prenatal and postnatal exposure showed no significant increase in concentration over  
747 time. The fetus is exposed to OPFRs through the amniotic fluid and breast milk. Many  
748 toxicological experiments and epidemiological studies have shown that maternal exposure to  
749 OPFRs may affect pregnancy outcomes and growth and development of the next generation.  
750 Furthermore, examining the predictors of maternal prenatal and postnatal exposure to OPFRs  
751 could help to reduce the potential adverse effects of OPFRs on mothers and fetuses. For better  
752 estimation of pregnant woman's exposure to OPFRs, recommendations on epidemiological and  
753 toxicological studies are provided as follows:

754 1) Due to the rapid metabolism of OPFRs in the body and their short biological half-lives,

755 only monitoring the levels of OPFRs in samples from pregnant women at one or two intervals  
756 during pregnancy may lead to bias in exposure doses. It is necessary to repeat monitoring during  
757 pregnancy and to estimate ICCs.

758 2) Human placental sampling in studies of mother-to-child transmission of OPFRs is  
759 complex. Animal models are essential for evaluating OPFR transmission in pregnant women  
760 and fetuses. Owing to the complexity of multiple physiological changes during pregnancy, more  
761 attention should be paid to hormonal alterations, epigenetics, inflammation/oxidative stress,  
762 cell injury, and nutrient absorption.

763 3) Because exposures to pollutants in the environment is complex and varied, much more  
764 attention should be paid to the synergistic effect of mixed pollutants in animal models. Future  
765 studies should consider the joint effects and nonlinear correlations of chemicals, and quantify  
766 the potential risks to mothers and infants.

767 4) Since the dose of exposure is related to the exposure and metabolism of OPFRs in vivo  
768 and the excretion of metabolites, the model test cannot accurately represent the exposure of  
769 pregnant women. To better extrapolate the results of animal models to humans, the  
770 toxicokinetics and excretion of OPFRs should be examined. A greater number of cohorts can  
771 be employed for correlation assessment in epidemiological investigations because the different  
772 metabolic abilities of individuals will lead to a significant variation in the mOPs levels of the  
773 sample.

774 5) Recent studies have shown that exposure to OPFRs during pregnancy has adverse effects  
775 on pregnant women, fetuses, and developmental risks of infants; however, the underlying  
776 mechanisms are unclear. Future research should provide mechanistic understanding of the sex-  
777 specific effects and identify the critical window of susceptibility of the fetus after exposure to  
778 OPFRs.

779 6) The OPFRs of mothers are transmitted to infants through breastfeeding, and it is necessary

780 to study the impact of OPFRs on the development of infants by studying the exposure of  
781 mothers after delivery. Analyzing the demographic characteristics of pregnant women such as  
782 diet, BMI, and personal care products, can facilitate the prediction and control of OPFRs during  
783 pregnancy, and the susceptible population should be managed accordingly.

## 784 **ASSOCIATED CONTENT**

### 785 **Supporting Information**

786 The Supporting Information is available free of charge at XXX.

787 Newcastle-Ottawa Scale for assessing the quality of included studies (Table S1), details of  
788 estimation of daily intakes, molecular structures and CAS numbers of the studied OPFRs and  
789 mOPs (Table S2), concentrations of mOPs and OPFRs in pregnant women urine (Table S3),  
790 and estimation of daily intake using urinary mOP concentrations (Table S4)

791

### 792 **Notes**

793 The authors declare no competing financial interest.

794

### 795 **Acknowledgments**

796 This work was jointly supported by the National Natural Science Foundation of China  
797 (22225605, 21906179, and 22193051), the National Key Research and Development Program  
798 of China (2020YFA0907500 and 2019YFC1604802), and the K.C. Wong Education  
799 Foundation of China (GJTD-2020-03).

800

801 **References**

- 802 1. Stapleton, H. M.; Allen, J. G.; Kelly, S. M.; Konstantinov, A.; Klosterhaus, S.; Watkins, D.; McClean,  
803 M. D.; Webster, T. F. Alternate and new brominated flame retardants detected in U.S. house dust.  
804 *Environ. Sci. Technol.* **2008**, *42*, 6910-6916.
- 805 2. Horrocks, A. R.; Davies, P. J.; Kandola, B. K.; Alderson, A. The potential for volatile phosphorus-  
806 containing flame retardants in textile back-coatings. *J. Fire. Sci.* **2016**, *25*, 523-540.
- 807 3. Li, X.; Wang, L.; Wang, Y.; Yao, Y.; Zhang, P.; Zhao, H.; Sun, H. Occupational exposure to  
808 organophosphate esters in e-waste dismantling workers: Risk assessment and influencing factors  
809 screening. *Ecotoxicol. Environ. Saf.* **2022**, *240*, 113707.
- 810 4. Wang, Y.; Yang, Y.; Zhang, Y.; Tan, F.; Li, Q.; Zhao, H.; Xie, Q.; Chen, J. Polyurethane heat preservation  
811 materials: The significant sources of organophosphorus flame retardants. *Chemosphere* **2019**, *227*, 409-  
812 415.
- 813 5. Hou, R.; Xu, Y.; Wang, Z. Review of OPFRs in animals and humans: Absorption, bioaccumulation,  
814 metabolism, and internal exposure research. *Chemosphere* **2016**, *153*, 78-90.
- 815 6. Li, W.; Wang, Y.; Asimakopoulos, A. G.; Covaci, A.; Gevao, B.; Johnson-Restrepo, B.; Kumosani, T. A.;  
816 Malarvannan, G.; Moon, H. B.; Nakata, H.; Sinha, R. K.; Tran, T. M.; Kannan, K. Organophosphate  
817 esters in indoor dust from 12 countries: Concentrations, composition profiles, and human exposure.  
818 *Environ. Int.* **2019**, *133*, 105178.
- 819 7. Castro-Jimenez, J.; Berrojalbiz, N.; Pizarro, M.; Dachs, J. Organophosphate ester (OPE) flame  
820 retardants and plasticizers in the open Mediterranean and Black Seas atmosphere. *Environ. Sci. Technol.*  
821 **2014**, *48*, 3203-9.
- 822 8. Huang, J.; Ye, L.; Fang, M.; Su, G. Industrial production of organophosphate flame retardants (OPFRs):  
823 Big knowledge gaps need to be filled? *Bull. Environ. Contam. Toxicol.* **2022**, *108*, 809-818.
- 824 9. Sundkvist, A. M.; Olofsson, U.; Haglund, P. Organophosphorus flame retardants and plasticizers in  
825 marine and fresh water biota and in human milk. *J. Environ. Monit.* **2010**, *12*, 943-951.
- 826 10. Suhring, R.; Diamond, M. L.; Scheringer, M.; Wong, F.; Pucko, M.; Stern, G.; Burt, A.; Hung, H.; Fellin,  
827 P.; Li, H.; Jantunen, L. M. Organophosphate esters in Canadian Arctic air: Occurrence, levels and trends.  
828 *Environ. Sci. Technol.* **2016**, *50*, 7409-15.
- 829 11. Li, J.; Xie, Z.; Mi, W.; Lai, S.; Tian, C.; Emeis, K. C.; Ebinghaus, R. Organophosphate esters in air,  
830 snow, and seawater in the North Atlantic and the Arctic. *Environ. Sci. Technol.* **2017**, *51*, 6887-6896.
- 831 12. Ren, G.; Chu, X.; Zhang, J.; Zheng, K.; Zhou, X.; Zeng, X.; Yu, Z. Organophosphate esters in the water,  
832 sediments, surface soils, and tree bark surrounding a manufacturing plant in north China. *Environ. Pollut.*  
833 **2019**, *246*, 374-380.

- 834 13. Liao, C.; Kim, U. J.; Kannan, K. Occurrence and distribution of organophosphate esters in sediment  
835 from northern Chinese coastal waters. *Sci. Total Environ.* **2020**, *704*, 135328.
- 836 14. Bekele, T. G.; Zhao, H.; Yang, J.; Chegen, R. G.; Chen, J.; Mekonen, S.; Qadeer, A. A review of  
837 environmental occurrence, analysis, bioaccumulation, and toxicity of organophosphate esters. *Environ.*  
838 *Sci. Pollut. Res. Int.* **2021**, *28*, 49507-49528.
- 839 15. Wong, F.; de Wit, C. A.; Newton, S. R. Concentrations and variability of organophosphate esters,  
840 halogenated flame retardants, and polybrominated diphenyl ethers in indoor and outdoor air in  
841 Stockholm, Sweden. *Environ. Pollut.* **2018**, *240*, 514-522.
- 842 16. Wang, X.; Zhu, Q.; Yan, X.; Wang, Y.; Liao, C.; Jiang, G. A review of organophosphate flame retardants  
843 and plasticizers in the environment: Analysis, occurrence and risk assessment. *Sci. Total Environ.* **2020**,  
844 *731*, 139071.
- 845 17. Langer, S.; Fredricsson, M.; Weschler, C. J.; Beko, G.; Strandberg, B.; Remberger, M.; Toftum, J.;  
846 Clausen, G. Organophosphate esters in dust samples collected from Danish homes and daycare centers.  
847 *Chemosphere* **2016**, *154*, 559-566.
- 848 18. Saillenfait, A. M.; Ndaw, S.; Robert, A.; Sabate, J. P. Recent biomonitoring reports on phosphate ester  
849 flame retardants: a short review. *Arch. Toxicol.* **2018**, *92*, 2749-2778.
- 850 19. Kim, J. W.; Isobe, T.; Muto, M.; Tue, N. M.; Katsura, K.; Malarvannan, G.; Sudaryanto, A.; Chang, K.  
851 H.; Prudente, M.; Viet, P. H.; Takahashi, S.; Tanabe, S. Organophosphorus flame retardants (PFRs) in  
852 human breast milk from several Asian countries. *Chemosphere* **2014**, *116*, 91-97.
- 853 20. Yao, C.; Yang, H.; Li, Y. A review on organophosphate flame retardants in the environment: Occurrence,  
854 accumulation, metabolism and toxicity. *Sci. Total Environ.* **2021**, *795*, 148837.
- 855 21. Meeker, J. D.; Stapleton, H. M. House dust concentrations of organophosphate flame retardants in  
856 relation to hormone levels and semen quality parameters. *Environ. Health Perspect.* **2010**, *118*, 318-323.
- 857 22. Liu, X.; Ji, K.; Choi, K. Endocrine disruption potentials of organophosphate flame retardants and related  
858 mechanisms in H295R and MVLN cell lines and in zebrafish. *Aquat. Toxicol.* **2012**, *114-115*, 173-81.
- 859 23. Kwon, B.; Shin, H.; Moon, H. B.; Ji, K.; Kim, K. T. Effects of tris(2-butoxyethyl) phosphate exposure  
860 on endocrine systems and reproduction of zebrafish (*Danio rerio*). *Environ. Pollut.* **2016**, *214*, 568-574.
- 861 24. Zhang, Y.; Li, M.; Li, S.; Wang, Q.; Zhu, G.; Su, G.; Letcher, R. J.; Liu, C. Exposure to tris(1,3-dichloro-  
862 2-propyl) phosphate for Two generations decreases fecundity of zebrafish at environmentally relevant  
863 concentrations. *Aquat. Toxicol.* **2018**, *200*, 178-187.
- 864 25. Patisaul, H. B. Accumulation and endocrine disrupting effects of the flame retardant mixture  
865 Firemaster(R) 550 in rats: an exploratory assessment. *J. Biochem. Mol. Toxicol.* **2013**, *27*, 124-136.
- 866 26. Zhang, Q.; Ji, C.; Yin, X.; Yan, L.; Lu, M.; Zhao, M. Thyroid hormone-disrupting activity and ecological

- 867 risk assessment of phosphorus-containing flame retardants by in vitro, in vivo and in silico approaches.  
868 *Environ. Pollut.* **2016**, *210*, 27-33.
- 869 27. Sly, P. D.; Carpenter, D. O.; Van den Berg, M.; Stein, R. T.; Landrigan, P. J.; Brune-Drisse, M. N.; Suk,  
870 W. Health consequences of environmental exposures: causal thinking in global environmental  
871 epidemiology. *Ann Glob Health* **2016**, *82*, 3-9.
- 872 28. Kahn, L. G.; Trasande, L. Environmental toxicant exposure and hypertensive disorders of pregnancy:  
873 Recent findings. *Curr. Hypertens. Rep.* **2018**, *20*, 87.
- 874 29. Ding, Y.; Han, M.; Wu, Z.; Zhang, R.; Li, A.; Yu, K.; Wang, Y.; Huang, W.; Zheng, X.; Mai, B.  
875 Bioaccumulation and trophic transfer of organophosphate esters in tropical marine food web, South  
876 China Sea. *Environ. Int.* **2020**, *143*, 105919.
- 877 30. Guigueno, M. F.; Fernie, K. J. Birds and flame retardants: A review of the toxic effects on birds of  
878 historical and novel flame retardants. *Environ. Res.* **2017**, *154*, 398-424.
- 879 31. Li, J.; Zhao, L.; Letcher, R. J.; Zhang, Y.; Jian, K.; Zhang, J.; Su, G. A review on organophosphate Ester  
880 (OPE) flame retardants and plasticizers in foodstuffs: Levels, distribution, human dietary exposure, and  
881 future directions. *Environ. Int.* **2019**, *127*, 35-51.
- 882 32. Wang, X.; Zhu, Q.; Liao, C.; Jiang, G. Human internal exposure to organophosphate esters: A short  
883 review of urinary monitoring on the basis of biological metabolism research. *J. Hazard. Mater.* **2021**,  
884 *418*, 126279.
- 885 33. Morgan, R. L.; Whaley, P.; Thayer, K. A.; Schunemann, H. J. Identifying the PECO: A framework for  
886 formulating good questions to explore the association of environmental and other exposures with health  
887 outcomes. *Environ. Int.* **2018**, *121*, 1027-1031.
- 888 34. Wells, G. S., B.; O'Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle–Ottawa  
889 Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. **2000**.
- 890 35. Lao, J.-Y.; Ruan, Y.; Leung, K. M. Y.; Zeng, E. Y.; Lam, P. K. S. Review on age-specific exposure to  
891 organophosphate esters: Multiple exposure pathways and microenvironments. *Crit. Rev. Environ. Sci.*  
892 *Technol.* **2022**, 1-24.
- 893 36. Bui, T. T.; Xu, F.; Van den Eede, N.; Cousins, A. P.; Covaci, A.; Cousins, I. T. Probing the relationship  
894 between external and internal human exposure of organophosphate flame retardants using  
895 pharmacokinetic modelling. *Environ. Pollut.* **2017**, *230*, 550-560.
- 896 37. Xu, F.; Tay, J. H.; Covaci, A.; Padilla-Sanchez, J. A.; Papadopoulou, E.; Haug, L. S.; Neels, H.; Sellstrom,  
897 U.; de Wit, C. A. Assessment of dietary exposure to organohalogen contaminants, legacy and emerging  
898 flame retardants in a Norwegian cohort. *Environ. Int.* **2017**, *102*, 236-243.
- 899 38. Poma, G.; Sales, C.; Bruyland, B.; Christia, C.; Gosciny, S.; Van Loco, J.; Covaci, A. Occurrence of

- 900 organophosphorus flame retardants and plasticizers (PFRs) in Belgian foodstuffs and estimation of the  
901 dietary exposure of the adult population. *Environ. Sci. Technol.* **2018**, *52*, 2331-2338.
- 902 39. He, C.; Wang, X.; Tang, S.; Thai, P.; Li, Z.; Baduel, C.; Mueller, J. F. Concentrations of organophosphate  
903 esters and their specific metabolites in food in southeast Queensland, Australia: Is dietary exposure an  
904 important pathway of organophosphate esters and their metabolites? *Environ. Sci. Technol.* **2018**, *52*,  
905 12765-12773.
- 906 40. Zhang, W.; Giesy, J. P.; Wang, P. Organophosphate esters in agro-foods: Occurrence, sources and  
907 emerging challenges. *Sci. Total Environ.* **2022**, *827*, 154271.
- 908 41. Lundqvist, A.; Johansson, I.; Wennberg, A.; Hultdin, J.; Högberg, U.; Hamberg, K.; Sandström, H.  
909 Reported dietary intake in early pregnant compared to non-pregnant women – a cross-sectional study.  
910 *BMC Pregnancy and Childbirth* **2014**, *14*, 373.
- 911 42. Koletzko, B.; Cetin, I.; Brenna, J. T. Dietary fat intakes for pregnant and lactating women. *Br. J. Nutr.*  
912 **2007**, *98*, 873-877.
- 913 43. Caut, C.; Leach, M.; Steel, A. Dietary guideline adherence during preconception and pregnancy: A  
914 systematic review. *Matern. Child. Nutr.* **2020**, *16*, e12916.
- 915 44. World Health Organization. WHO recommendations on antenatal care for a positive pregnancy  
916 experience. <https://www.who.int/publications/i/item/9789241549912> (accessed March 3, 2023).
- 917 45. Wang, X.; Wang, W.; Zhu, Q.; Wang, Y.; Liao, C.; Jiang, G. Organophosphate esters in foodstuffs from  
918 multiple provinces in china: Possible sources during food processing and implications for human  
919 exposure. *J. Agric. Food Chem.* **2022**, *70*, 8609-8618.
- 920 46. Chen, X.; Fan, S.; Lyu, B.; Zhang, L.; Yao, S.; Liu, J.; Shi, Z.; Wu, Y. Occurrence and dietary intake of  
921 organophosphate esters via animal-origin food consumption in China: Results of a chinese total diet  
922 study. *J. Agric. Food Chem.* **2021**, *69*, 13964-13973.
- 923 47. Li, M.; Fei, J.; Zhang, Z.; Sun, Q.; Liu, C. Organophosphate esters in Chinese rice: Occurrence,  
924 distribution, and human exposure risks. *Sci. Total Environ.* **2023**, *862*, 160915.
- 925 48. Wang, Y.; Zhang, Z.; Bao, M.; Xu, Y.; Zhang, L.; Tan, F.; Zhao, H. Characteristics and risk assessment  
926 of organophosphate esters and phthalates in soils and vegetation from Dalian, northeast China. *Environ.*  
927 *Pollut.* **2021**, *284*, 117532.
- 928 49. Wang, Y.; Kannan, K. Concentrations and dietary exposure to organophosphate esters in foodstuffs from  
929 Albany, New York, United States. *J. Agric. Food Chem.* **2018**, *66*, 13525-13532.
- 930 50. Chupeau, Z.; Bonvallot, N.; Mercier, F.; Le Bot, B.; Chevrier, C.; Glorennec, P. Organophosphorus  
931 flame retardants: A global review of indoor contamination and human exposure in Europe and  
932 epidemiological evidence. *Int. J. Environ. Res. Public Health* **2020**, *17*.

- 933 51. Cao, D.; Lv, K.; Gao, W.; Fu, J.; Wu, J.; Fu, J.; Wang, Y.; Jiang, G. Presence and human exposure  
934 assessment of organophosphate flame retardants (OPEs) in indoor dust and air in Beijing, China.  
935 *Ecotoxicol. Environ. Saf.* **2019**, *169*, 383-391.
- 936 52. Schreder, E. D.; Uding, N.; La Guardia, M. J. Inhalation a significant exposure route for chlorinated  
937 organophosphate flame retardants. *Chemosphere* **2016**, *150*, 499-504.
- 938 53. Ouidir, M.; Giorgis-Allemand, L.; Lyon-Caen, S.; Morelli, X.; Cracowski, C.; Pontet, S.; Pin, I.; Lepeule,  
939 J.; Siroux, V.; Slama, R. Estimation of exposure to atmospheric pollutants during pregnancy integrating  
940 space-time activity and indoor air levels: Does it make a difference? *Environ. Int.* **2015**, *84*, 161-173.
- 941 54. Valero, N.; Aguilera, I.; Llop, S.; Esplugues, A.; de Nazelle, A.; Ballester, F.; Sunyer, J. Concentrations  
942 and determinants of outdoor, indoor and personal nitrogen dioxide in pregnant women from two Spanish  
943 birth cohorts. *Environ. Int.* **2009**, *35*, 1196-1201.
- 944 55. Nethery, E.; Brauer, M.; Janssen, P. Time-activity patterns of pregnant women and changes during the  
945 course of pregnancy. *J. Expo. Sci. Environ. Epidemiol.* **2009**, *19*, 317-324.
- 946 56. Choi, H.; Perera, F.; Pac, A.; Wang, L.; Flak, E.; Mroz, E.; Jacek, R.; Chai-Onn, T.; Jedrychowski, W.;  
947 Masters, E.; Camann, D.; Spengler, J. Estimating individual-level exposure to airborne polycyclic  
948 aromatic hydrocarbons throughout the gestational period based on personal, indoor, and outdoor  
949 monitoring. *Environ. Health Perspect.* **2008**, *116*, 1509-1518.
- 950 57. Yi, L.; Xu, Y.; Eckel, S. P.; O'Connor, S.; Cabison, J.; Rosales, M.; Chu, D.; Chavez, T. A.; Johnson, M.;  
951 Mason, T. B.; Bastain, T. M.; Breton, C. V.; Dunton, G. F.; Wilson, J. P.; Habre, R. Time-activity and  
952 daily mobility patterns during pregnancy and early postpartum - evidence from the MADRES cohort.  
953 *Spat Spatiotemporal Epidemiol* **2022**, *41*, 100502.
- 954 58. Zhang, B.; Lu, S.; Huang, M.; Zhou, M.; Zhou, Z.; Zheng, H.; Jiang, Y.; Bai, X.; Zhang, T. Urinary  
955 metabolites of organophosphate flame retardants in 0-5-year-old children: Potential exposure risk for  
956 inpatients and home-stay infants. *Environ. Pollut.* **2018**, *243*, 318-325.
- 957 59. Yadav, I. C.; Devi, N. L.; Zhong, G.; Li, J.; Zhang, G.; Covaci, A. Occurrence and fate of  
958 organophosphate ester flame retardants and plasticizers in indoor air and dust of Nepal: Implication for  
959 human exposure. *Environ. Pollut.* **2017**, *229*, 668-678.
- 960 60. Yang, C.; Harris, S. A.; Jantunen, L. M.; Siddique, S.; Kubwabo, C.; Tsirlin, D.; Latifovic, L.; Fraser,  
961 B.; St-Jean, M.; De La Campa, R.; You, H.; Kulka, R.; Diamond, M. L. Are cell phones an indicator of  
962 personal exposure to organophosphate flame retardants and plasticizers? *Environ. Int.* **2019**, *122*, 104-  
963 116.
- 964 61. Zhang, Q.; Li, X.; Wang, Y.; Zhang, C.; Cheng, Z.; Zhao, L.; Li, X.; Sun, Z.; Zhang, J.; Yao, Y.; Wang,  
965 L.; Li, W.; Sun, H. Occurrence of novel organophosphate esters derived from organophosphate

- 966 antioxidants in an e-waste dismantling area: Associations between hand wipes and dust. *Environ. Int.*  
967 **2021**, *157*, 106860.
- 968 62. Ingle, M. E.; Watkins, D.; Rosario, Z.; Velez Vega, C. M.; Huerta-Montanez, G.; Calafat, A. M.; Ospina,  
969 M.; Cordero, J. F.; Alshawabkeh, A.; Meeker, J. D. The association of urinary organophosphate ester  
970 metabolites and self-reported personal care and household product use among pregnant women in Puerto  
971 Rico. *Environ. Res.* **2019**, *179*, 108756.
- 972 63. Doherty, B. T.; Pearce, J. L.; Anderson, K. A.; Karagas, M. R.; Romano, M. E. Assessment of  
973 multipollutant exposures during pregnancy using silicone wristbands. *Front Public Health* **2020**, *8*,  
974 547239.
- 975 64. Ingle, M. E.; Minguez-Alarcon, L.; Carignan, C. C.; Butt, C. M.; Stapleton, H. M.; Williams, P. L.; Ford,  
976 J. B.; Hauser, R.; Meeker, J. D.; Team, E. S. The association of urinary phosphorous-containing flame  
977 retardant metabolites and self-reported personal care and household product use among couples seeking  
978 fertility treatment. *J. Expo. Sci. Environ. Epidemiol.* **2020**, *30*, 107-116.
- 979 65. Li, Y.; Chen, R.; He, J.; Ma, H.; Zhao, F.; Tao, S.; Liu, J.; Hu, J. Triphenyl phosphate at environmental  
980 levels retarded ovary development and reduced egg production in Japanese medaka (*Oryzias Latipes*).  
981 *Environ. Sci. Technol.* **2019**, *53*, 14709-14715.
- 982 66. Hu, W.; Gao, P.; Wang, L.; Hu, J. Endocrine disrupting toxicity of aryl organophosphate esters and mode  
983 of action. *Crit. Rev. Environ. Sci. Technol.* **2022**, *53*, 1-18.
- 984 67. McGee, S. P.; Cooper, E. M.; Stapleton, H. M.; Volz, D. C. Early zebrafish embryogenesis is susceptible  
985 to developmental TDCPP exposure. *Environ. Health Perspect.* **2012**, *120*, 1585-1591.
- 986 68. Li, R.; Wang, H.; Mi, C.; Feng, C.; Zhang, L.; Yang, L.; Zhou, B. The adverse effect of TCIPP and TCEP  
987 on neurodevelopment of zebrafish embryos/larvae. *Chemosphere* **2019**, *220*, 811-817.
- 988 69. Zhong, X.; Qiu, J.; Kang, J.; Xing, X.; Shi, X.; Wei, Y. Exposure to tris(1,3-dichloro-2-propyl) phosphate  
989 (TDCPP) induces vascular toxicity through Nrf2-VEGF pathway in zebrafish and human umbilical vein  
990 endothelial cells. *Environ. Pollut.* **2019**, *247*, 293-301.
- 991 70. Chan, M.; Mita, C.; Bellavia, A.; Parker, M.; James-Todd, T. Racial/ethnic disparities in pregnancy and  
992 prenatal exposure to endocrine-disrupting chemicals commonly used in personal care products. *Curr*  
993 *Environ Health Rep* **2021**, *8*, 98-112.
- 994 71. Dodson, R. E.; Cardona, B.; Zota, A. R.; Robinson Flint, J.; Navarro, S.; Shamasunder, B. Personal care  
995 product use among diverse women in California: Taking Stock Study. *J. Expo. Sci. Environ. Epidemiol.*  
996 **2021**, *31*, 487-502.
- 997 72. Soma-Pillay, P.; Nelson-Piercy, C.; Tolppanen, H.; Mebazaa, A. Physiological changes in pregnancy.  
998 *Cardiovasc J Afr* **2016**, *27*, 89-94.

- 999 73. Grandjean, P.; Barouki, R.; Bellinger, D. C.; Casteleyn, L.; Chadwick, L. H.; Cordier, S.; Etzel, R. A.;  
1000 Gray, K. A.; Ha, E. H.; Junien, C.; Karagas, M.; Kawamoto, T.; Paige Lawrence, B.; Perera, F. P.; Prins,  
1001 G. S.; Puga, A.; Rosenfeld, C. S.; Sherr, D. H.; Sly, P. D.; Suk, W.; Sun, Q.; Toppari, J.; van den Hazel,  
1002 P.; Walker, C. L.; Heindel, J. J. Life-long implications of developmental exposure to environmental  
1003 stressors: New perspectives. *Endocrinology* **2015**, *156*, 3408-15.
- 1004 74. Rice, D.; Barone, S. Critical periods of vulnerability for the developing nervous system: evidence from  
1005 humans and animal models. *Environ. Health Perspect.* **2000**, *108*, 511-533.
- 1006 75. Haddow, J. E.; Palomaki, G. E.; Allan, W. C.; Williams, J. R.; Knight, G. J.; Gagnon, J.; O'Heir, C. E.;  
1007 Mitchell, M. L.; Hermos, R. J.; Waisbren, S. E.; Faix, J. D.; Klein, R. Z. Maternal thyroid deficiency  
1008 during pregnancy and subsequent neuropsychological development of the child. *N. Engl. J. Med.* **1999**,  
1009 *341*, 549-555.
- 1010 76. Barr, D. B.; Bishop, A.; Needham, L. L. Concentrations of xenobiotic chemicals in the maternal-fetal  
1011 unit. *Reprod. Toxicol.* **2007**, *23*, 260-266.
- 1012 77. Gore, A. C.; Martien, K. M.; Gagnidze, K.; Pfaff, D. Implications of prenatal steroid perturbations for  
1013 neurodevelopment, behavior, and autism. *Endocr. Rev.* **2014**, *35*, 961-991.
- 1014 78. Aylward, L. L.; Hays, S. M.; Kirman, C. R.; Marchitti, S. A.; Kenneke, J. F.; English, C.; Mattison, D.  
1015 R.; Becker, R. A. Relationships of chemical concentrations in maternal and cord blood: a review of  
1016 available data. *J. Toxicol. Environ. Health B Crit. Rev.* **2014**, *17*, 175-203.
- 1017 79. Hoffman, K.; Lorenzo, A.; Butt, C. M.; Adair, L.; Herring, A. H.; Stapleton, H. M.; Daniels, J. L.  
1018 Predictors of urinary flame retardant concentration among pregnant women. *Environ. Int.* **2017**, *98*, 96-  
1019 101.
- 1020 80. Hoffman, K.; Stapleton, H. M.; Lorenzo, A.; Butt, C. M.; Adair, L.; Herring, A. H.; Daniels, J. L. Prenatal  
1021 exposure to organophosphates and associations with birthweight and gestational length. *Environ. Int.*  
1022 **2018**, *116*, 248-254.
- 1023 81. Song, S.; Tian, Q.; Tong, L.; Pan, M.; Ma, S. Novel method to determine the lipid content of breast milk.  
1024 *Chemosphere* **2017**, *168*, 279-283.
- 1025 82. Hoffman, K.; Daniels, J. L.; Stapleton, H. M. Urinary metabolites of organophosphate flame retardants  
1026 and their variability in pregnant women. *Environ. Int.* **2014**, *63*, 169-172.
- 1027 83. Liu, C.; Wang, Q.; Liang, K.; Liu, J.; Zhou, B.; Zhang, X.; Liu, H.; Giesy, J. P.; Yu, H. Effects of tris(1,3-  
1028 dichloro-2-propyl) phosphate and triphenyl phosphate on receptor-associated mRNA expression in  
1029 zebrafish embryos/larvae. *Aquat. Toxicol.* **2013**, *128-129*, 147-57.
- 1030 84. Yang, W.; Braun, J. M.; Vuong, A. M.; Percy, Z.; Xu, Y.; Xie, C.; Deka, R.; Calafat, A. M.; Ospina, M.;  
1031 Werner, E.; Yolton, K.; Cecil, K. M.; Lanphear, B. P.; Chen, A. Maternal urinary OPE metabolite

- 1032 concentrations and blood pressure during pregnancy: The HOME study. *Environ. Res.* **2022**, *207*,  
1033 112220.
- 1034 85. Percy, Z.; Vuong, A. M.; Ospina, M.; Calafat, A. M.; La Guardia, M. J.; Xu, Y.; Hale, R. C.; Dietrich,  
1035 K. N.; Xie, C.; Lanphear, B. P.; Braun, J. M.; Cecil, K. M.; Yolton, K.; Chen, A. Organophosphate esters  
1036 in a cohort of pregnant women: Variability and predictors of exposure. *Environ. Res.* **2020**, *184*, 109255.
- 1037 86. Tao, Y.; Hu, L.; Liu, L.; Yu, M.; Li, Y.; Li, X.; Liu, W.; Luo, D.; Covaci, A.; Xia, W.; Xu, S.; Li, Y.; Mei,  
1038 S. Prenatal exposure to organophosphate esters and neonatal thyroid-stimulating hormone levels: A birth  
1039 cohort study in Wuhan, China. *Environ. Int.* **2021**, *156*, 106640.
- 1040 87. Romano, M. E.; Hawley, N. L.; Eliot, M.; Calafat, A. M.; Jayatilaka, N. K.; Kelsey, K.; McGarvey, S.;  
1041 Phipps, M. G.; Savitz, D. A.; Werner, E. F.; Braun, J. M. Variability and predictors of urinary  
1042 concentrations of organophosphate flame retardant metabolites among pregnant women in Rhode Island.  
1043 *Environ. Health* **2017**, *16*, 40.
- 1044 88. Deziel, N. C.; Yi, H.; Stapleton, H. M.; Huang, H.; Zhao, N.; Zhang, Y. A case-control study of exposure  
1045 to organophosphate flame retardants and risk of thyroid cancer in women. *BMC Cancer* **2018**, *18*, 637.
- 1046 89. Kuiper, J. R.; Stapleton, H. M.; Wills-Karp, M.; Wang, X.; Burd, I.; Buckley, J. P. Predictors and  
1047 reproducibility of urinary organophosphate ester metabolite concentrations during pregnancy and  
1048 associations with birth outcomes in an urban population. *Environ. Health* **2020**, *19*, 55.
- 1049 90. Cao, J.; Wang, Q.; Lei, Y.; Jiang, X.; Li, M. Accumulation of microplastics and Tcep pollutants in  
1050 agricultural soil: Exploring the links between metabolites and gut microbiota in earthworm homeostasis.  
1051 *Environ. Int.* **2022**, *170*, 107590.
- 1052 91. Li, F.; Meng, X.; Wang, X.; Ji, C.; Wu, H. Graphene-triphenyl phosphate (TPP) co-exposure in the  
1053 marine environment: Interference with metabolism and immune regulation in mussel *Mytilus*  
1054 *galloprovincialis*. *Ecotoxicol. Environ. Saf.* **2021**, *227*, 112904.
- 1055 92. Preston, E. V.; McClean, M. D.; Claus Henn, B.; Stapleton, H. M.; Braverman, L. E.; Pearce, E. N.;  
1056 Makey, C. M.; Webster, T. F. Associations between urinary diphenyl phosphate and thyroid function.  
1057 *Environ. Int.* **2017**, *101*, 158-164.
- 1058 93. Lee, G.; Kim, S.; Bastiaensen, M.; Malarvannan, G.; Poma, G.; Caballero Casero, N.; Gys, C.; Covaci,  
1059 A.; Lee, S.; Lim, J. E.; Mok, S.; Moon, H. B.; Choi, G.; Choi, K. Exposure to organophosphate esters,  
1060 phthalates, and alternative plasticizers in association with uterine fibroids. *Environ. Res.* **2020**, *189*,  
1061 109874.
- 1062 94. Wang, X.; Liu, Q.; Zhong, W.; Yang, L.; Yang, J.; Covaci, A.; Zhu, L. Estimating renal and hepatic  
1063 clearance rates of organophosphate esters in humans: Impacts of intrinsic metabolism and binding  
1064 affinity with plasma proteins. *Environ. Int.* **2020**, *134*, 105321.

- 1065 95. Van den Eede, N.; Maho, W.; Erratico, C.; Neels, H.; Covaci, A. First insights in the metabolism of  
1066 phosphate flame retardants and plasticizers using human liver fractions. *Toxicol. Lett.* **2013**, *223*, 9-15.
- 1067 96. Liu, Y.; Li, Y.; Dong, S.; Han, L.; Guo, R.; Fu, Y.; Zhang, S.; Chen, J. The risk and impact of  
1068 organophosphate esters on the development of female-specific cancers: Comparative analysis of patients  
1069 with benign and malignant tumors. *J. Hazard. Mater.* **2021**, *404*, 124020.
- 1070 97. Hu, W.; Gao, F.; Zhang, H.; Hiromori, Y.; Arakawa, S.; Nagase, H.; Nakanishi, T.; Hu, J. Activation of  
1071 peroxisome proliferator-activated receptor gamma and disruption of progesterone synthesis of 2-  
1072 ethylhexyl diphenyl phosphate in human placental choriocarcinoma cells: Comparison with triphenyl  
1073 phosphate. *Environ. Sci. Technol.* **2017**, *51*, 4061-4068.
- 1074 98. Chen, R.; Hou, R.; Hong, X.; Yan, S.; Zha, J. Organophosphate flame retardants (OPFRs) induce  
1075 genotoxicity in vivo: A survey on apoptosis, DNA methylation, DNA oxidative damage, liver  
1076 metabolites, and transcriptomics. *Environ. Int.* **2019**, *130*, 104914.
- 1077 99. Chen, G.; Jin, Y.; Wu, Y.; Liu, L.; Fu, Z. Exposure of male mice to two kinds of organophosphate flame  
1078 retardants (OPFRs) induced oxidative stress and endocrine disruption. *Environ. Toxicol. Pharmacol.*  
1079 **2015**, *40*, 310-318.
- 1080 100. St-Pierre, J.; Laurent, L.; King, S.; Vaillancourt, C. Effects of prenatal maternal stress on serotonin and  
1081 fetal development. *Placenta* **2016**, *48 Suppl 1*, S66-S71.
- 1082 101. Gao, K.; Zhuang, T.; Liu, X.; Fu, J.; Zhang, J.; Fu, J.; Wang, L.; Zhang, A.; Liang, Y.; Song, M.; Jiang,  
1083 G. Prenatal exposure to per- and polyfluoroalkyl substances (PFASs) and association between the  
1084 placental transfer efficiencies and dissociation constant of serum proteins-PFAS complexes. *Environ.*  
1085 *Sci. Technol.* **2019**, *53*, 6529-6538.
- 1086 102. Li, X.; Sun, H.; Yao, Y.; Zhao, Z.; Qin, X.; Duan, Y.; Wang, L. Distribution of phthalate metabolites  
1087 between paired maternal-fetal samples. *Environ. Sci. Technol.* **2018**, *52*, 6626-6635.
- 1088 103. Michael R. Syme, J. W. P. a. J. A. K. Drug transfer and metabolism by the human placenta. *Clin.*  
1089 *Pharmacokinet.* **2004**, *43*, 487-514.
- 1090 104. Fleming, A.; Gerrelli, D.; Greene, N. D.; Copp, A. Mechanisms of normal and abnormal neurulation:  
1091 Evidence from embryo culture studies. *Int. J. Dev. Biol.* **1997**, *41*, 199-212.
- 1092 105. Zhao, F.; Chen, M.; Gao, F.; Shen, H.; Hu, J. Organophosphorus flame retardants in pregnant women  
1093 and their transfer to chorionic villi. *Environ. Sci. Technol.* **2017**, *51*, 6489-6497.
- 1094 106. Robins, J. C.; Marsit, C. J.; Padbury, J. F.; Sharma, S. S. Endocrine disruptors, environmental oxygen,  
1095 epigenetics and pregnancy. *Front Biosci (Elite Ed)*. **2011**, *3*, 690-700.
- 1096 107. Zhang, X.; Cheng, X.; Lei, B.; Zhang, G.; Bi, Y.; Yu, Y. A review of the transplacental transfer of  
1097 persistent halogenated organic pollutants: Transfer characteristics, influential factors, and mechanisms.

- 1098 *Environ. Int.* **2021**, *146*, 106224.
- 1099 108. Ding, J.; Xu, Z.; Huang, W.; Feng, L.; Yang, F. Organophosphate ester flame retardants and plasticizers  
1100 in human placenta in Eastern China. *Sci. Total Environ.* **2016**, *554-555*, 211-217.
- 1101 109. Baldwin, K. R.; Phillips, A. L.; Horman, B.; Arambula, S. E.; Rebuli, M. E.; Stapleton, H. M.; Patisaul,  
1102 H. B. Sex specific placental accumulation and behavioral effects of developmental Firemaster 550  
1103 exposure in Wistar rats. *Sci Rep* **2017**, *7*, 7118.
- 1104 110. Wang, X.; Chen, P.; Zhao, L.; Zhu, L.; Wu, F. Transplacental behaviors of organophosphate tri- and  
1105 diesters based on paired human maternal and cord whole blood: Efficiencies and impact factors. *Environ.*  
1106 *Sci. Technol.* **2021**, *55*, 3091-3100.
- 1107 111. Phillips, A. L.; Chen, A.; Rock, K. D.; Horman, B.; Patisaul, H. B.; Stapleton, H. M. Transplacental and  
1108 lactational transfer of Firemaster(R) 550 components in dosed Wistar rats. *Toxicol. Sci.* **2016**, *153*, 246-  
1109 257.
- 1110 112. Ahmed E, A.; Sam, J.; Salah, S.; Nabila, A.; Khalid, O.; Jiann-Ping, L.; Natasha, R. Whole-body  
1111 autoradiographic disposition, elimination and placental transport of [<sup>14</sup>C]tri-o-cresyl phosphate in mice.  
1112 *J. Appl. Toxicol.* **1993**, *13*, 259-267.
- 1113 113. Kozikowska, I.; Binkowski, L. J.; Szczepanska, K.; Slawska, H.; Miszczuk, K.; Sliwinska, M.; Laciak,  
1114 T.; Stawarz, R. Mercury concentrations in human placenta, umbilical cord, cord blood and amniotic  
1115 fluid and their relations with body parameters of newborns. *Environ. Pollut.* **2013**, *182*, 256-262.
- 1116 114. Toft, G.; Jonsson, B. A.; Bonde, J. P.; Norgaard-Pedersen, B.; Hougaard, D. M.; Cohen, A.; Lindh, C.  
1117 H.; Ivell, R.; Anand-Ivell, R.; Lindhard, M. S. Perfluorooctane sulfonate concentrations in amniotic fluid,  
1118 biomarkers of fetal Leydig Cell function, and cryptorchidism and hypospadias in Danish boys (1980-  
1119 1996). *Environ. Health Perspect.* **2016**, *124*, 151-156.
- 1120 115. Luzardo, O. P.; Mahtani, V.; Troyano, J. M.; Alvarez de la Rosa, M.; Padilla-Perez, A. I.; Zumbado, M.;  
1121 Almeida, M.; Burillo-Putze, G.; Boada, C.; Boada, L. D. Determinants of organochlorine levels  
1122 detectable in the amniotic fluid of women from Tenerife Island (Canary Islands, Spain). *Environ. Res.*  
1123 **2009**, *109*, 607-613.
- 1124 116. Bai, X. Y.; Lu, S. Y.; Xie, L.; Zhang, B.; Song, S. M.; He, Y.; Ouyang, J. P.; Zhang, T. A pilot study of  
1125 metabolites of organophosphorus flame retardants in paired maternal urine and amniotic fluid samples:  
1126 potential exposure risks of tributyl phosphate to pregnant women. *Environ Sci Process Impacts* **2019**,  
1127 *21*, 124-132.
- 1128 117. Lehmann, G. M.; LaKind, J. S.; Davis, M. H.; Hines, E. P.; Marchitti, S. A.; Alcala, C.; Lorber, M.  
1129 Environmental chemicals in breast milk and formula: Exposure and risk assessment implications.  
1130 *Environ. Health Perspect.* **2018**, *126*, 96001.

- 1131 118. Fariás, P.; Rodríguez-Dozal, S.; Baltazar-Reyes, M. C.; Gold-Bouchot, G.; Zapata-Pérez, O.; Loreto-  
1132 Gómez, C.; Riojas-Rodríguez, H. Persistent organic pollutants in serum and breast milk of fertile-aged  
1133 women. *Rev Int de Contam* **2019**, *35*, 281-293.
- 1134 119. Ma, J.; Zhu, H.; Kannan, K. Organophosphorus flame retardants and plasticizers in breast milk from the  
1135 United States. *Environ Sci Technol Lett* **2019**, *6*, 525-531.
- 1136 120. Chen, T.; Huang, M.; Li, J.; Li, J.; Shi, Z. Polybrominated diphenyl ethers and novel brominated flame  
1137 retardants in human milk from the general population in Beijing, China: Occurrence, temporal trends,  
1138 nursing infants' exposure and risk assessment. *Sci. Total Environ.* **2019**, *689*, 278-286.
- 1139 121. He, C.; Toms, L. L.; Thai, P.; Van den Eede, N.; Wang, X.; Li, Y.; Baduel, C.; Harden, F. A.; Heffernan,  
1140 A. L.; Hobson, P.; Covaci, A.; Mueller, J. F. Urinary metabolites of organophosphate esters:  
1141 Concentrations and age trends in Australian children. *Environ. Int.* **2018**, *111*, 124-130.
- 1142 122. Van den Eede, N.; Tomy, G.; Tao, F.; Halldorson, T.; Harrad, S.; Neels, H.; Covaci, A. Kinetics of tris  
1143 (1-chloro-2-propyl) phosphate (TCIPP) metabolism in human liver microsomes and serum.  
1144 *Chemosphere* **2016**, *144*, 1299-305.
- 1145 123. Zheng, G.; Schreder, E.; Dempsey, J. C.; Uding, N.; Chu, V.; Andres, G.; Sathyanarayana, S.; Salamova,  
1146 A. Organophosphate esters and their metabolites in breast milk from the United States: Breastfeeding is  
1147 an important exposure pathway for infants. *Environ Sci Technol Lett* **2021**, *8*, 224-230.
- 1148 124. U.S. Environmental Protection Agency. Regional screening levels (RSLs)-user's guide.  
1149 <https://www.epa.gov/risk/regional-screening-levels-rsls-users-guide> (accessed September 30, 2022).
- 1150 125. Kim, J. W.; Isobe, T.; Sudaryanto, A.; Malarvannan, G.; Chang, K. H.; Muto, M.; Prudente, M.; Tanabe,  
1151 S. Organophosphorus flame retardants in house dust from the Philippines: occurrence and assessment  
1152 of human exposure. *Environ. Sci. Pollut. Res. Int.* **2013**, *20*, 812-822.
- 1153 126. Gibson, E. A.; Stapleton, H. M.; Calero, L.; Holmes, D.; Burke, K.; Martinez, R.; Cortes, B.;  
1154 Nematollahi, A.; Evans, D.; Anderson, K. A.; Herbstman, J. B. Differential exposure to organophosphate  
1155 flame retardants in mother-child pairs. *Chemosphere* **2019**, *219*, 567-573.
- 1156 127. Zhang, R.; Li, N.; Li, J.; Zhao, C.; Luo, Y.; Wang, Y.; Jiang, G. Percutaneous absorption and exposure  
1157 risk assessment of organophosphate esters in children's toys. *J. Hazard. Mater.* **2022**, *440*, 129728.
- 1158 128. Chen, N.; Fan, S.; Zhang, N.; Zhao, Y.; Yao, S.; Chen, X.; Liu, X.; Shi, Z. Organophosphate esters and  
1159 their diester metabolites in infant formulas and baby supplementary foods collected in Beijing, China:  
1160 Occurrence and the implications for infant exposure. *Sci. Total Environ.* **2022**, *827*, 154272.
- 1161 129. Chen, X.; Zhao, X.; Shi, Z. Organophosphorus flame retardants in breast milk from Beijing, China:  
1162 Occurrence, nursing infant's exposure and risk assessment. *Sci. Total Environ.* **2021**, *771*, 145404.
- 1163 130. Tue, N. M.; Sudaryanto, A.; Minh, T. B.; Nhat, B. H.; Isobe, T.; Takahashi, S.; Viet, P. H.; Tanabe, S.


- 1164 Kinetic differences of legacy organochlorine pesticides and polychlorinated biphenyls in Vietnamese  
1165 human breast milk. *Chemosphere* **2010**, *81*, 1006-1011.
- 1166 131. Du, Z.; Wang, G.; Gao, S.; Wang, Z. Aryl organophosphate flame retardants induced cardiotoxicity  
1167 during zebrafish embryogenesis: by disturbing expression of the transcriptional regulators. *Aquat.*  
1168 *Toxicol.* **2015**, *161*, 25-32.
- 1169 132. Qi, Z.; Chen, M.; Song, Y.; Wang, X.; Li, B.; Chen, Z. F.; Tsang, S. Y.; Cai, Z. Acute exposure to  
1170 triphenyl phosphate inhibits the proliferation and cardiac differentiation of mouse embryonic stem cells  
1171 and zebrafish embryos. *J. Cell. Physiol.* **2019**, *234*, 21235-21248.
- 1172 133. Liu, Y.; Wu, D.; Xu, Q.; Yu, L.; Liu, C.; Wang, J. Acute exposure to tris (2-butoxyethyl) phosphate  
1173 (TBOEP) affects growth and development of embryo-larval zebrafish. *Aquat. Toxicol.* **2017**, *191*, 17-  
1174 24.
- 1175 134. Wang, Q.; Liang, K.; Liu, J.; Yang, L.; Guo, Y.; Liu, C.; Zhou, B. Exposure of zebrafish embryos/larvae  
1176 to TDCPP alters concentrations of thyroid hormones and transcriptions of genes involved in the  
1177 hypothalamic-pituitary-thyroid axis. *Aquat. Toxicol.* **2013**, *126*, 207-213.
- 1178 135. Li, R.; Guo, W.; Lei, L.; Zhang, L.; Liu, Y.; Han, J.; Chen, L.; Zhou, B. Early-life exposure to the  
1179 organophosphorus flame-retardant tris (1,3-dichloro-2-propyl) phosphate induces delayed neurotoxicity  
1180 associated with DNA methylation in adult zebrafish. *Environ. Int.* **2020**, *134*, 105293.
- 1181 136. McGee, S. P.; Konstantinov, A.; Stapleton, H. M.; Volz, D. C. Aryl phosphate esters within a major  
1182 PentaBDE replacement product induce cardiotoxicity in developing zebrafish embryos: potential role  
1183 of the aryl hydrocarbon receptor. *Toxicol. Sci.* **2013**, *133*, 144-156.
- 1184 137. Mitchell, C. A.; Reddam, A.; Dasgupta, S.; Zhang, S.; Stapleton, H. M.; Volz, D. C. Diphenyl phosphate-  
1185 induced toxicity during embryonic development. *Environ. Sci. Technol.* **2019**, *53*, 3908-3916.
- 1186 138. Mitchell, C. A.; Dasgupta, S.; Zhang, S.; Stapleton, H. M.; Volz, D. C. Disruption of nuclear receptor  
1187 signaling alters triphenyl phosphate-induced cardiotoxicity in zebrafish embryos. *Toxicol. Sci.* **2018**,  
1188 *163*, 307-318.
- 1189 139. Shi, Q.; Wang, M.; Shi, F.; Yang, L.; Guo, Y.; Feng, C.; Liu, J.; Zhou, B. Developmental neurotoxicity  
1190 of triphenyl phosphate in zebrafish larvae. *Aquat. Toxicol.* **2018**, *203*, 80-87.
- 1191 140. Dasgupta, S.; Vliet, S. M.; Kupsco, A.; Leet, J. K.; Altomare, D.; Volz, D. C. Tris(1,3-dichloro-2-propyl)  
1192 phosphate disrupts dorsoventral patterning in zebrafish embryos. *PeerJ* **2017**, *5*, e4156.
- 1193 141. Rhyu, D.; Lee, H.; Tanguay, R. L.; Kim, K. T. Tris(1,3-dichloro-2-propyl)phosphate (TDCIPP) disrupts  
1194 zebrafish tail fin development. *Ecotoxicol. Environ. Saf.* **2019**, *182*, 109449.
- 1195 142. Guigueno, M. F.; Head, J. A.; Letcher, R. J.; Karouna-Renier, N.; Peters, L.; Hanas, A. M.; Fernie, K. J.  
1196 Early life exposure to triphenyl phosphate: Effects on thyroid function, growth, and resting metabolic

- 1197 rate of Japanese quail (*Coturnix japonica*) chicks. *Environ. Pollut.* **2019**, *253*, 899-908.
- 1198 143. Kanda, K.; Ito, S.; Koh, D. H.; Kim, E. Y.; Iwata, H. Effects of tris(2-chloroethyl) phosphate exposure  
1199 on chicken embryos in a shell-less incubation system. *Ecotoxicol. Environ. Saf.* **2021**, *207*, 111263.
- 1200 144. Rock., K. D.; Horman., B.; Phillips., A. L. EDC IMPACT: Molecular effects of developmental FM 550  
1201 exposure in Wistar rat placenta and fetal forebrain. *ENDOCCR CONNECT* **2018**.
- 1202 145. Yin, S. Y.; Chen, L.; Wu, D. Y.; Wang, T.; Huo, L. J.; Zhao, S.; Zhou, J.; Zhang, X.; Miao, Y. L. Tris(1,3-  
1203 dichloro-2-propyl) phosphate disturbs mouse embryonic development by inducing apoptosis and  
1204 abnormal DNA methylation. *Environ. Mol. Mutagen.* **2019**, *60*, 807-815.
- 1205 146. Alzualde, A.; Behl, M.; Sipes, N. S.; Hsieh, J. H.; Alday, A.; Tice, R. R.; Paules, R. S.; Muriana, A.;  
1206 Quevedo, C. Toxicity profiling of flame retardants in zebrafish embryos using a battery of assays for  
1207 developmental toxicity, neurotoxicity, cardiotoxicity and hepatotoxicity toward human relevance.  
1208 *Neurotoxicol. Teratol.* **2018**, *70*, 40-50.
- 1209 147. Luo, D.; Liu, W.; Tao, Y.; Wang, L.; Yu, M.; Hu, L.; Zhou, A.; Covaci, A.; Xia, W.; Li, Y.; Xu, S.; Mei,  
1210 S. Prenatal exposure to organophosphate flame retardants and the risk of low birth weight: A nested  
1211 case-control study in China. *Environ. Sci. Technol.* **2020**, *54*, 3375-3385.
- 1212 148. Luo, D.; Liu, W.; Wu, W.; Tao, Y.; Hu, L.; Wang, L.; Yu, M.; Zhou, A.; Covaci, A.; Xia, W.; Xu, S.; Li,  
1213 Y.; Mei, S. Trimester-specific effects of maternal exposure to organophosphate flame retardants on  
1214 offspring size at birth: A prospective cohort study in China. *J. Hazard. Mater.* **2021**, *406*, 124754.
- 1215 149. Percy, Z.; Vuong, A. M.; Xu, Y.; Xie, C.; Ospina, M.; Calafat, A. M.; Hoofnagle, A.; Lanphear, B. P.;  
1216 Braun, J. M.; Cecil, K. M.; Dietrich, K. N.; Yolton, K.; Chen, A. Maternal urinary organophosphate  
1217 esters and alterations in maternal and neonatal thyroid hormones. *Am. J. Epidemiol.* **2021**, *190*, 1793-  
1218 180.
- 1219 150. Yao, Y.; Li, M.; Pan, L.; Duan, Y.; Duan, X.; Li, Y.; Sun, H. Exposure to organophosphate ester flame  
1220 retardants and plasticizers during pregnancy: Thyroid endocrine disruption and mediation role of  
1221 oxidative stress. *Environ. Int.* **2021**, *146*, 106215.
- 1222 151. Crawford, K. A.; Hawley, N.; Calafat, A. M.; Jayatilaka, N. K.; Froehlich, R. J.; Has, P.; Gallagher, L.  
1223 G.; Savitz, D. A.; Braun, J. M.; Werner, E. F.; Romano, M. E. Maternal urinary concentrations of  
1224 organophosphate ester metabolites: associations with gestational weight gain, early life anthropometry,  
1225 and infant eating behaviors among mothers-infant pairs in Rhode Island. *Environ. Health* **2020**, *19*, 97.
- 1226 152. Bommarito, P. A.; Welch, B. M.; Keil, A. P.; Baker, G. P.; Cantonwine, D. E.; McElrath, T. F.; Ferguson,  
1227 K. K. Prenatal exposure to consumer product chemical mixtures and size for gestational age at delivery.  
1228 *Environ. Health* **2021**, *20*, 68.
- 1229 153. Zhao, Y.; Ding, J.; Lv, L.; Zhang, H. Exposure to organophosphate flame esters during early pregnancy

- 1230 and risk of spontaneous abortion: A case-control study. *Chemosphere* **2021**, *268*, 129375.
- 1231 154. Carignan, C. C.; Minguéz-Alarcon, L.; Butt, C. M.; Williams, P. L.; Meeker, J. D.; Stapleton, H. M.;  
1232 Toth, T. L.; Ford, J. B.; Hauser, R.; Team, E. S. Urinary concentrations of organophosphate flame  
1233 retardant metabolites and pregnancy outcomes among women undergoing in vitro fertilization. *Environ.*  
1234 *Health Perspect.* **2017**, *125*, 087018.
- 1235 155. Farhat, A.; Crump, D.; Chiu, S.; Williams, K. L.; Letcher, R. J.; Gauthier, L. T.; Kennedy, S. W. In Ovo  
1236 effects of two organophosphate flame retardants--TCPP and TDCPP--on pipping success, development,  
1237 mRNA expression, and thyroid hormone levels in chicken embryos. *Toxicol. Sci.* **2013**, *134*, 92-102.
- 1238 156. Moser, V. C.; Phillips, P. M.; Hedge, J. M.; McDaniel, K. L. Neurotoxicological and thyroid evaluations  
1239 of rats developmentally exposed to tris(1,3-dichloro-2-propyl)phosphate (TDCIPP) and tris(2-chloro-2-  
1240 ethyl)phosphate (TCEP). *Neurotoxicol. Teratol.* **2015**, *52*, 236-247.
- 1241 157. Liu, X.; Cai, Y.; Wang, Y.; Xu, S.; Ji, K.; Choi, K. Effects of tris(1,3-dichloro-2-propyl) phosphate  
1242 (TDCPP) and triphenyl phosphate (TPP) on sex-dependent alterations of thyroid hormones in adult  
1243 zebrafish. *Ecotoxicol. Environ. Saf.* **2019**, *170*, 25-32.
- 1244 158. Egloff, C.; Crump, D.; Porter, E.; Williams, K. L.; Letcher, R. J.; Gauthier, L. T.; Kennedy, S. W. Tris(2-  
1245 butoxyethyl)phosphate and triethyl phosphate alter embryonic development, hepatic mRNA expression,  
1246 thyroid hormone levels, and circulating bile acid concentrations in chicken embryos. *Toxicol. Appl.*  
1247 *Pharmacol.* **2014**, *279*, 303-310.
- 1248 159. Hu, F.; Zhao, Y.; Yuan, Y.; Yin, L.; Dong, F.; Zhang, W.; Chen, X. Effects of environmentally relevant  
1249 concentrations of tris (2-chloroethyl) phosphate (TCEP) on early life stages of zebrafish (*Danio rerio*).  
1250 *Environ. Toxicol. Pharmacol.* **2021**, *83*, 103600.
- 1251 160. Carignan, C. C.; Minguéz-Alarcon, L.; Williams, P. L.; Meeker, J. D.; Stapleton, H. M.; Butt, C. M.;  
1252 Toth, T. L.; Ford, J. B.; Hauser, R.; Team, E. S. Paternal urinary concentrations of organophosphate  
1253 flame retardant metabolites, fertility measures, and pregnancy outcomes among couples undergoing in  
1254 vitro fertilization. *Environ. Int.* **2018**, *111*, 232-238.
- 1255 161. Messerlian, C.; Williams, P. L.; Minguéz-Alarcon, L.; Carignan, C. C.; Ford, J. B.; Butt, C. M.; Meeker,  
1256 J. D.; Stapleton, H. M.; Souter, I.; Hauser, R.; Team, E. S. Organophosphate flame-retardant metabolite  
1257 concentrations and pregnancy loss among women conceiving with assisted reproductive technology.  
1258 *Fertil. Steril.* **2018**, *110*, 1137-1144 e1.
- 1259 162. Stirrat, G. M. Recurrent miscarriage. *Lancet* **1990**, *336*, 673-675.
- 1260 163. Ingle, M. E.; Watkins, D.; Rosario, Z.; VelezVega, C. M.; Calafat, A. M.; Ospina, M.; Ferguson, K. K.;  
1261 Cordero, J. F.; Alshwabkeh, A.; Meeker, J. D. An exploratory analysis of urinary organophosphate ester  
1262 metabolites and oxidative stress among pregnant women in Puerto Rico. *Sci. Total Environ.* **2020**, *703*,

- 1263 134798.
- 1264 164. Lipscomb, S. T.; McClelland, M. M.; MacDonald, M.; Cardenas, A.; Anderson, K. A.; Kile, M. L. Cross-  
1265 sectional study of social behaviors in preschool children and exposure to flame retardants. *Environ.*  
1266 *Health* **2017**, *16*, 23.
- 1267 165. Bennett, D.; Bellinger, D. C.; Birnbaum, L. S.; Bradman, A.; Chen, A.; Cory-Slechta, D. A.; Engel, S.  
1268 M.; Fallin, M. D.; Halladay, A.; Hauser, R.; Hertz-Picciotto, I.; Kwiatkowski, C. F.; Lanphear, B. P.;  
1269 Marquez, E.; Marty, M.; McPartland, J.; Newschaffer, C. J.; Payne-Sturges, D.; Patisaul, H. B.; Perera,  
1270 F. P.; Ritz, B.; Sass, J.; Schantz, S. L.; Webster, T. F.; Whyatt, R. M.; Woodruff, T. J.; Zoeller, R. T.;  
1271 Anderko, L.; Campbell, C.; Conry, J. A.; DeNicola, N.; Gould, R. M.; Hirtz, D.; Huffling, K.; Landrigan,  
1272 P. J.; Lavin, A.; Miller, M.; Mitchell, M. A.; Rubin, L.; Schettler, T.; Tran, H. L.; Acosta, A.; Brody, C.;  
1273 Miller, E.; Miller, P.; Swanson, M.; Witherspoon, N. O.; American College of, O.; Gynecologists; Child  
1274 Neurology, S.; Endocrine, S.; International Neurotoxicology, A.; International Society for Children's,  
1275 H.; the, E.; International Society for Environmental, E.; National Council of Asian Pacific Islander, P.;  
1276 National Hispanic Medical, A.; National Medical, A. Project TENDR: Targeting environmental neuro-  
1277 developmental risks the TENDR consensus statement. *Environ. Health Perspect.* **2016**, *124*, A118-22.
- 1278 166. Doherty, B. T.; Hammel, S. C.; Daniels, J. L.; Stapleton, H. M.; Hoffman, K. Organophosphate esters:  
1279 Are these flame retardants and plasticizers affecting children's health? *Curr Environ Health Rep* **2019**,  
1280 *6*, 201-213.
- 1281 167. Shi, Q.; Tsui, M. M. P.; Hu, C.; Lam, J. C. W.; Zhou, B.; Chen, L. Acute exposure to triphenyl phosphate  
1282 (TPHP) disturbs ocular development and muscular organization in zebrafish larvae. *Ecotoxicol. Environ.*  
1283 *Saf.* **2019**, *179*, 119-126.
- 1284 168. Green, A. J. Perinatal triphenyl phosphate exposure accelerates type 2 diabetes onset and increases  
1285 adipose accumulation in UCD-type 2 diabetes mellitus rats. *Reprod. Toxicol.* **2017**, *68*, 119-129.
- 1286 169. Wang, D.; Yan, S.; Yan, J.; Teng, M.; Meng, Z.; Li, R.; Zhou, Z.; Zhu, W. Effects of triphenyl phosphate  
1287 exposure during fetal development on obesity and metabolic dysfunctions in adult mice: Impaired lipid  
1288 metabolism and intestinal dysbiosis. *Environ. Pollut.* **2019**, *246*, 630-638.
- 1289 170. Hanas, A. K.; Guigueno, M. F.; Fernie, K. J.; Letcher, R. J.; Ste-Marie Chamberland, F.; Head, J. A.  
1290 Assessment of the effects of early life exposure to triphenyl phosphate on fear, boldness, aggression,  
1291 and activity in Japanese quail (*Coturnix japonica*) chicks. *Environ. Pollut.* **2020**, *258*, 113695.
- 1292 171. Zhao, Y.; Yin, L.; Dong, F.; Zhang, W.; Hu, F. Effects of tris (2-chloroethyl) phosphate (TCEP) on  
1293 survival, growth, histological changes and gene expressions in juvenile yellow catfish *Pelteobagrus*  
1294 *fulvidraco*. *Environ. Toxicol. Pharmacol.* **2021**, *87*, 103699.
- 1295 172. Wiersielis, K. R.; Adams, S.; Yasrebi, A.; Conde, K.; Roepke, T. A. Maternal exposure to  
1296 organophosphate flame retardants alters locomotor and anxiety-like behavior in male and female adult


- 1297 offspring. *Horm. Behav.* **2020**, *122*, 104759.
- 1298 173. Kamishima, M.; Hattori, T.; Suzuki, G. Early-life exposure to tris(1,3-dichloroisopropyl) phosphate  
1299 induces dose-dependent suppression of sexual behavior in male rats. *J. Appl. Toxicol.* **2018**, *38*, 649-  
1300 655.
- 1301 174. Cheng, R.; Jia, Y.; Dai, L.; Liu, C.; Wang, J.; Li, G.; Yu, L. Tris(1,3-dichloro-2-propyl) phosphate  
1302 disrupts axonal growth, cholinergic system and motor behavior in early life zebrafish. *Aquat. Toxicol.*  
1303 **2017**, *192*, 7-15.
- 1304 175. Araki, A.; Bastiaensen, M.; Ait Bamai, Y.; Van den Eede, N.; Kawai, T.; Tsuboi, T.; Ketema, R. M.;  
1305 Covaci, A.; Kishi, R. Associations between allergic symptoms and phosphate flame retardants in dust  
1306 and their urinary metabolites among school children. *Environ. Int.* **2018**, *119*, 438-446.
- 1307 176. Navaranjan, G.; Jantunen, L. M.; Diamond, M. L.; Harris, S. A.; Bernstein, S.; Scott, J. A.; Takaro, T.  
1308 K.; Dai, R.; Lefebvre, D. L.; Mandhane, P. J.; Moraes, T. J.; Simons, E.; Turvey, S. E.; Sears, M. R.;  
1309 Subbarao, P.; Brook, J. R. Early life exposure to tris(2-butoxyethyl) phosphate (TBOEP) is related to  
1310 the development of childhood asthma. *Environ. Sci. Technol.* **2021**, *8*, 531-537.
- 1311 177. Castorina, R.; Bradman, A.; Stapleton, H. M.; Butt, C.; Avery, D.; Harley, K. G.; Gunier, R. B.; Holland,  
1312 N.; Eskenazi, B. Current-use flame retardants: Maternal exposure and neurodevelopment in children of  
1313 the CHAMACOS cohort. *Chemosphere* **2017**, *189*, 574-580.
- 1314 178. Liu, W.; Luo, D.; Xia, W.; Tao, Y.; Wang, L.; Yu, M.; Hu, L.; Zhou, A.; Covaci, A.; Lin, C.; Xu, S.; Mei,  
1315 S.; Li, Y. Prenatal exposure to halogenated, aryl, and alkyl organophosphate esters and child  
1316 neurodevelopment at two years of age. *J. Hazard. Mater.* **2021**, *408*, 124856.
- 1317



1318


1319

**Figure 1.** A flow diagram showing the selection of literatures



1320 **Figure 2. (a)** Concentrations of mOPs in urine samples of pregnant women worldwide. **(b)** Concentrations of OPFRs  
 1321 in breast milk samples of pregnant women worldwide. The data above the histogram represents the median  
 1322 concentration of OPFRs or mOPs in ng/mL. The sampling period is below the city. The data for “America 2009-  
 1323 2012” represent the mean concentration of OPFRs. The data of Japan, Philippines, Vietnam, and Swedish were  
 1324 converted from the average lipid content (40 mg lipid/g).<sup>81</sup>

1325



1326

1327 **Figure 3.** Predictors, sources, and monitoring of OPFRs or mOPs in pregnant women before and after

1328 delivery. The figure only contains the predictors, sources, and monitor methods discussed in the review.

**Table 1. Sample Collection Times and ICCs**

Location	Sampling period	SG-corrected ICCs (95% CI)									
		DNBP	DPHP	BDCIPP	BBOEP	DoCP & DpCP	BCIPHIPP	BCIPP	BCEP	ip-PPP	tb-PPP
Wuhan, China	first ( $12.9 \pm 0.9$ weeks), second ( $24.7 \pm 3.6$ weeks), and third trimesters ( $34.0 \pm 3.1$ weeks)	0.26 (0.14, 0.39)	0.16 (0.04, 0.29)	0.17 (0.05, 0.30)	0.09 (- 0.02, 0.21)	0.19 (0.07, 0.32)	0.16 (0.04, 0.29)	/	/	/	/
Wuhan, China	before 16 weeks and after 28 weeks of gestation	/	0.32 (0.21, 0.46)	0.26 (0.15, 0.41)	0.21 (0.10, 0.37)	0.27 (0.16, 0.42)	0.08 (0.01, 0.38)	/	/	/	/
Cincinnati, Ohio, America	16 weeks, 26 weeks of pregnancy and after delivery	0.20	0.16	0.36	/	/	/	/	0.34	/	/
Northern Puerto Rico, America	18 weeks and 26 weeks of gestation	/	0.25 (0.13, 0.43)	0.23 (0.11, 0.41)	/	/	/	0.34 (0.21, 0.49)	0.03 (0.00, 0.86)	/	/
Baltimore, Maryland, America	15.3 ( $\pm 3.1$ ) weeks, 22.3 ( $\pm 2.2$ ) weeks at the second visit, and 30.9 ( $\pm 2.5$ ) weeks	/	0.27 (0.15, 0.43)	0.59 (0.45, 0.73)	/	/	/	/	/	0.09 (0.01, 0.44)	0.19 (0.08, 0.38)
Rhode Island, America	12 weeks, 28 weeks and 35 weeks of gestation	/	0.43	0.6	/	/	/	/	0.5	/	/
North Carolina, America	18 weeks, 28 weeks of pregnancy and 1–10 days after delivery	/	0.4 (0.2, 0.6)	0.4 (0.2, 0.6)	/	/	/	/	/	/	/

ICCs: intraclass correlation coefficients

1330


1331

**Table 2. Estimated Daily Intakes (ng/kg bw/day) of OPFRs of High Concern via Breast Feeding**

Sampling location	OPFRs	TNBP	TCrP	TPHP	TBOEP	TCEP	TDCIPP	TCIPP	TEHP	EHDPP
	RfD	2400	1300	7000	1500	7000	20000	3600	35000	600
South East Queensland, Australian	< 1 month	93	34.5	84	21	39	10.4	795	405	/
	1-3 months	86.8	32.2	78.4	19.6	36.4	9.66	742	378	/
	3-6 months	68.2	25.3	61.6	15.4	28.6	7.59	583	297	/
	6-12 months	51.5	19.1	46.5	11.6	21.6	5.73	439.9	224.1	/
Beijing, China	< 1 month	5.01	/	160.5	35.4	31.1	7.07	103.35	220.5	126.6
	1-3 months	4.68	/	149.8	33.0	29.0	6.59	96.46	205.8	118.16
	3-6 months	3.67	/	117.7	26.0	22.8	5.18	75.79	161.7	92.8
	6-12 months	2.77	/	88.8	19.6	17.2	3.91	57.19	122.01	70.1
Tennessee, Wisconsin, South Dakota, Maine, New York, Pennsylvania, North Carolina, and California (America)	< 1 month	80.9	3.15	22.4	216	5.4	/	33.15	36.75	3.3
	1-3 months	75.5	2.94	20.9	201.6	5.04	/	30.94	34.3	3.08
	3-6 months	59.3	2.31	16.4	158.4	3.96	/	24.31	27.0	2.42
	6-12 months	44.7	1.74	12.4	119.52	2.99	/	18.34	20.3	1.83
Kanagawa Prefecture, Japan	< 1 month	2.34	/	8.4	1.44	0.84	/	/	/	/
	1-3 months	2.18	/	7.84	1.34	0.78	/	/	/	/
	3-6 months	1.72	/	6.16	1.06	0.62	/	/	/	/
	6-12 months	1.29	/	4.65	0.80	0.46	/	/	/	/
Payatas, Philippines	< 1 month	NA	10.2	114	132	246	/	/	/	/
	1-3 months	0	9.52	106.4	123.2	229.6	/	/	/	/
	3-6 months	0	7.48	83.6	96.8	180.4	/	/	/	/
	6-12 months	0	5.64	63.1	73.0	136.1	/	/	/	/
Malate, Philippines	< 1 month	14.4	15	120	/	252	/	/	/	/
	1-3 months	13.4	14	112	/	235.2	/	/	/	/

	3-6 months	10.6	11	88	/	184.8	/	/	/	/
	6-12 months	7.97	8.3	66.4	/	139.44	/	/	/	/
	< 1 month	7.80	2.04	30	/	/	/	/	/	/
Hanoi, Vietnam	1-3 months	7.28	1.90	28	/	/	/	/	/	/
	3-6 months	5.72	1.50	22	/	/	/	/	/	/
	6-12 months	4.32	1.13	16.6	/	/	/	/	/	/
	< 1 month	21	4.98	48.6	/	/	/	/	/	/
Bui Dau, Vietnam	1-3 months	19.6	4.65	45.36	/	/	/	/	/	/
	3-6 months	15.4	3.65	35.64	/	/	/	/	/	/
	6-12 months	11.6	2.76	26.89	/	/	/	/	/	/
	< 1 month	10.8	/	1.68	/	/	/	/	/	/
Trang Minh, Vietnam	1-3 months	10.1	/	1.568	/	/	/	/	/	/
	3-6 months	7.92	/	1.232	/	/	/	/	/	/
	6-12 months	5.98	/	0.93	/	/	/	/	/	/
	< 1 month	65.9	/	7.41	65.85	/	/	220.5	117.6	/
Seattle, America	1-3 months	61.5	/	6.92	61.46	/	/	205.8	109.76	/
	3-6 months	48.3	/	5.43	48.29	/	/	161.7	86.2	/
	6-12 months	36.4	/	4.10	36.44	/	/	122.01	65.1	/
	< 1 month	72	4.8	51	28.2	29.4	25.8	270	/	39
Uppsala, Lycksele, Lund, Umea (Swedish)	1-3 months	67.2	4.48	47.6	26.32	27.44	24.1	252	/	36.4
	3-6 months	52.8	3.52	37.4	20.68	21.56	18.9	198	/	28.6
	6-12 months	39.8	2.66	28.22	15.60	16.27	14.3	149.4	/	21.6

1334 **Graphical Abstract**



1335

1336

1337

1338